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ABSTRACT: Alzheimer’s disease (AD) is a complex, multifactorial disease in
which different neuropathological mechanisms are likely involved, including those
associated with pathological tau and Aβ species as well as neuroinflammation.
In this context, the development of single multitargeted therapeutics directed against
two or more disease mechanisms could be advantageous. Starting from a series of
1,5-diarylimidazoles with microtubule (MT)-stabilizing activity and structural
similarities with known NSAIDs, we conducted structure−activity relationship
studies that led to the identification of multitargeted prototypes with activities
as MT-stabilizing agents and/or inhibitors of the cyclooxygenase (COX) and
5-lipoxygenase (5-LOX) pathways. Several examples are brain-penetrant and exhibit
balanced multitargeted in vitro activity in the low μM range. As brain-penetrant
MT-stabilizing agents have proven effective against tau-mediated neurodegeneration
in animal models, and because COX- and 5-LOX-derived eicosanoids are thought to
contribute to Aβ plaque deposition, these 1,5-diarylimidazoles provide tools to
explore novel multitargeted strategies for AD and other neurodegenerative diseases.
■ INTRODUCTION
In Alzheimer’s disease (AD), aggregated tau proteins and Aβ
peptides are thought to participate in disease onset and
progression. Moreover, other factors such as neuroinflamma-
tion and oxidative stress are also believed to be intimately
associated with the neurodegenerative process. Although the
precise relationship(s) linking these different neuropathological
mechanisms remain the focus of active research, it is clear
that AD is a complex and multifactorial disease. Thus far, Aβ
amyloidosis has been the target of choice in AD drug discovery,
as most drug candidates have been designed to modulate Aβ
homeostasis. However, in spite of generally strong preclinical
data with such therapeutic candidates, the outcomes of late-stage
AD clinical trials have thus far failed to demonstrate clinical
efficacy. These disappointing results raise the possibility that
AD treatments may have to interfere concurrently with more
than one neuropathological mechanism to exert disease
modifying benefits. In this context, a single multitargeted drug
may have distinctive advantages in terms of efficacy and safety
over drug combination therapies.1 As such, an increasing number
of therapeutic strategies that are based on polypharmacology
have been proposed for AD.2,3
Over the past several years, our laboratories and others have
demonstrated that brain-penetrant MT-stabilizing agents have
profoundly beneficial effects in animal models of tau pathology
due to the ability of these compounds to normalize hyper-
dynamic axonal MTs, restore axonal transport, reduce the burden
of tau pathology, and prevent cognitive impairments and neuron
loss associated with tau pathology.4−7 Furthermore, our recent
work8 indicates that the binding of cyclooxygenase (COX)- and
5-lipoxygenase (5-LOX)-derived eicosanoids to their cognate
receptors in neurons results in increased production of amyloid
precursor protein (APP) and Aβ peptides, adding to a body
of literature9−23 implicating inflammatory eicosanoids as key
contributing factors to Aβ plaque deposition in AD. Thus, a
stabilization of axonal MTs, combined with a concurrent
suppression of eicosanoid production, may be considered as a
multitargeted therapeutic strategy that could attenuate both tau-
and Aβ-mediated neurodegeneration, as well as MT deficiencies24
and/or neuroinflammation,25−31 in AD. Moreover, this approach
may also provide benefit in other neurodegenerative tauopathies.
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The rational design of multitargeted compounds is challeng-
ing, especially when attempting to merge multiple molecular
frameworks and the corresponding underlying pharmacophores
in a single small molecule.32 However, a series of fungicidal
diaryl-pyrazoles (e.g., 1, Figure 1) and -imidazoles (e.g., 2, Figure 1)
with known MT-stabilizing activity exhibit tricyclic structures
similar to those found in known nonsteroidal anti-inflammatory
drugs (NSAIDs) such as the potent COX-1 inhibitor33 SC560
(3, Figure 1) and, to a lesser extent, the dual COX/5-LOX
inhibitor34 licofelone (4, Figure 1). Furthermore, molecular
docking studies indicated that selected representative examples
of these MT-stabilizing imidazoles could fit within the
arachidonic acid binding site of COX-1 with a predicted binding
energy that is comparable (i.e., within 2 kcal/mol) to that of 3
(see Figure 1 and Supporting Information). Thus, although
MT-stabilizing agents and NSAIDs are different classes of
biologically active compounds that interact with unrelated
targets, the observed structural commonalities between these
compounds suggest that there may be significant degree of
crosstalk between the different pharmacophores that could be
exploited to identify multitargeted ligands. Toward this end, the
synthesis and subsequent evaluation of several closely related
1,5-diarylimidazole congeners led to the identification of specific
substitution patterns that are required to achieve different
activity profiles in vitro. In particular, in addition to identifying
compounds that act selectively as MT-stabilizers and others that
are selective inhibitors of the COX- and/or 5-LOX pathways
with no effect on MTs, these studies led to the identification of a
series of multitargeted molecules that at low μM concentration
can concurrently stabilize MTs and inhibit both COX- and
5-LOX derived eicosanoids in cell-based assays. Furthermore,
several of these compounds were also confirmed to be brain-
penetrant, indicating that molecules of this type may be
considered as potential multitargeted prototype structures for
AD and related tauopathies.
■ RESULTS
Chemistry. As part of these studies, a library comprising
81 imidazoles has been synthesized, including 36 known
compounds (i.e., 2, 25, 29−31, 35, 36, 38, 43−46, 51, 54, 55,
57, 58, 61, 62, 64, 65, 67, 68, 70, 71, 73, 74, 83−86, 88, 92, 94,
95, and 97, Table 1), most with reported antifungal35 or
antimicrobial activity, as well as 45 new structures (i.e., 26−28,
32−34, 37, 39−42, 47−50, 52, 53, 56, 59, 60, 63, 66, 69, 72,
75−82, 87, 89−91, 93, 96, 98−104, Table 1). In general, the
synthesis of the 1,5-diarylimidazoles was conducted following
the Van Leusen imidazole synthesis.36 Thus, after condensation
of the appropriate aryl-amine and benzaldehyde, the resulting
Schiff base (5−24, Scheme 1) was cyclized in the presence of
toluenesulfonylmethyl isocyanide (TosMIC) to form the
1,5-diarylimidazole (25−28, 32, 33, 37−43, 47−53, Scheme 1).
Further derivatizations of the imidazole ring included the
introduction of small alkyl groups and/or halogens in position 2
and/or 4 (29−31, 34−36, and 44−46 in Scheme 1 and 54−104
in Scheme 2). Imidazole derivatives bearing a methyl substituent at
C4 were accessed by employing the appropriately C-substituted
TosMIC reagent during the cyclization step (29, 35, 44), while
alkylated derivatives at C2 (e.g., 34, 86) were obtained by treating
the appropriate 1,5-diarylimidazole with LDA followed by addition
of the desired alkyl iodide. Finally, halogenation of the imidazole
ring was accomplished upon treatment with N-chlorosuccinimide.
When the halogenation was carried out on imidazoles that were
not substituted at C2 and C4, the reaction typically proceeded
with the generation of separable mixtures of mono- and
dichlorinated imidazoles.
Structure−Activity Relationships. The MT-stabilizing
activity of test compounds was determined in QBI-293 cells
by monitoring compound-induced elevation in acetylated
α-tubulin (AcTub),37 which is a known marker of stable MTs.38
Furthermore, as the MT-stabilizing imidazoles are believed to
act on MTs in a manner similar to that described for the
triazolopyrimidines,35 and considering that certain triazolopyr-
Figure 1. (A) Comparison of representative examples of fungicidal diaryl-pyrazoles (1) and -imidazoles (2) with reported MT-stabilizing activity, with
known COX- (3) and dual COX/5-LOX (4) inhibitors; molecular docking of 2 (B) and 3 (C) within the arachidonic acid binding site of COX-1.
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imidines have been found to induce a proteasome-dependent
degradation of α-tubulin,39 the effect of compound treatment on
total α-tubulin was also monitored. Evaluation of compound
inhibition of the biosynthesis of COX- and 5-LOX-derived
eicosanoids was conducted in a modified rat basophilic leukemia
(RBL-1) cell assay that has previously been described40 for the
evaluation of 5-LOX and which we found can be used to assess
both COX-derived prostaglandins (PGs) and 5-LOX-derived
leukotrienes (LTs) formed in the presence or absence of test
compounds.
All compounds were initially screened at 1 and 10 μM
concentration in the QBI cell MT assay and at 10 μM in the
RBL-1 cell assay (Table 1). In this initial RBL-1 cell analysis,
5-LOX-derived LTB4 and COX-derived PGD2 and PGE2, which
coeluted during LC/MS/MS, were quantified. Selected com-
pounds (Table 2) exhibiting evidence of multitargeted activity
underwent further confirmatory studies in the RBL-1 cell assay,
which included concentration−response testing, and further
LC/MS/MS analyses using a refined protocol to individually
detect and quantitate PGD2 and PGE2, as well as both LTB4 and
LTC4. As the formation of each of these eicosanoids depends
on separate enzymatic steps in the COX or 5-LOX pathways,41
concurrent analysis of all four of these eicosanoids provides a
convenient and reliable method to evaluate the overall effect
of test compounds on COX and 5-LOX pathways in a cellular
milieu. Finally, several compounds in Table 2 were also assessed
for their relative brain-to-plasma exposure levels after admin-
istration to mice.
MT-Stabilizing Activity. Evaluation of compounds in the
QBI-293 cell MT assay revealed that out of 71 tested compounds,
48 examples exhibited activity on MTs as revealed by
statistically significant changes in AcTub levels. Among
MT-active compounds, seven examples (i.e., 2, 58, 65, 71,
85, 86, and 97) were found to be active at 1 μM compound
concentration, whereas the remaining 41 compounds were
active only at 10 μM. Consistent with the notion that the
MT-stabilizing 1,5-diarylimidazoles may be acting on MTs in a
similar manner as the triazolopyrimidines,35 the data presented
in Table 1 reveal that like the latter molecules, these imidazoles
can be broadly divided into two subsets: one group of
15 entries, which cause a significant reduction in total α-tubulin
levels at doses typically required to induce an elevation in
AcTub (i.e., 2, 30, 34, 58, 62, 63, 65, 66, 71, 73, 85, 94−97)
and a second group of 33 compounds that produce an elevation
in AcTub at 1 or 10 μM without decreasing α-tubulin level
(29, 31, 35, 36, 44−46, 54, 55−57, 59, 60, 64, 67−70, 72, 74,
78, 82−84, 86−88, 90−93, 102, 104). Also of interest, a
comparison of the activities of compounds in the AcTub assay
at 1 and 10 μM suggest that selected entries, such as compounds
2, 58, and 71, may exhibit a bell-shaped concentration−
response relationship, and it is possible that additional examples
would show a similar concentration−response if tested at higher
concentrations. This phenomenon was observed in the case
of the triazolopyrimidines that reduce α-tubulin level, such as
108.39 Irrespective of whether or not test compounds cause
a reduction in total α-tubulin, the AcTub SAR emerging from
the data shown in Table 1 appear to be in general agree-
ment with SAR from prior studies in which MT-stabilizing
1,5-diarylimidazoles were evaluated for antifungal activity.35
Thus, our results indicate that ring A is preferably a 4-chloro-
Scheme 1a
aReagents and reaction conditions: (a) Dean−Stark apparatus, toluene, 110 °C, 4 days, 99%; (b) 4 Å molecular sieves, Et2O, 30 °C, 48 h, 99%;
(c) appropriate TosMIC reagent, K2CO3, DMF/1,2-dimethoxyethane, 100 °C, 16 h, 7−90%; (d) N-chlorosuccinimide, CHCl3, 60 °C, 16 h,
43−71%; (e) LDA, methyliodide, THF, −20 °C to rt, 1.5 h, 29−56%.
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phenyl, although examples bearing other substituents in the
para-position, such as a trifluoromethoxy (83), are also active.
Additional substitutions in the A ring, as in compound 77 and
78 in which a fluorine is present in the ortho-position, appear to
impact negatively MT interactions of the compound (cf. 77 with
87 and 78 with 84). With respect to the B ring, the degree and
pattern of fluorination appear to be generally important factors
that determine the ability of these imidazoles to produce a
significant elevation in the marker of stable MTs in QBI-293
cells. Whereas derivatives with either one or no fluorination
in the B ring (i.e., 50, 51, 75, 76, 98−101) were found to be
essentially devoid of MT activity in our assay conditions, other
di- and trisubstituted congeners (e.g., 54, 68, 84) produced a
significant increase in AcTub. Furthermore, a comparison
between the inactive difluorinated derivative 80 and the active
di- and trifluorinated compounds (i.e., 54, 68, and 84) suggests
that the presence of two fluorine atoms in the ortho-positions of
ring B is required for MT activity. Finally, with respect to the
imidazole ring (ring C), our results indicate that 1,5-diary-
limidazoles that are not substituted in positions 2 and 4 (e.g.,
25, 26, 42, 43, 48, 49, 52, and 53) do not cause a detectable
increase in AcTub, whereas tetrasubstituted imidazoles,
including C2/C4 dihalogenated (e.g., 88) and dimethylated
(e.g., 46) derivatives, as well as analogues bearing both a small
alkyl- and a chloro-substituent in either C2 or C4 positions
(e.g., 85 and 45), are generally more active than corresponding
derivatives bearing a single substitution in either position 2 or 4
(cf. 87, 88, and 44, 46). These results also suggest that MT
activity does not strictly require a halogen in position 4 of the
imidazole ring, as was required for optimal antifungal activity,35
because congeners halogenated at C2 appear to retain comparable
MT activity (cf. 54, 56 and 84, 87).
Inhibition of Prostaglandin Biosynthetic Pathway.
Evaluation of test compounds as potential inhibitors of COX-
dependent formation of PGD2/PGE2 in RBL-1 cells revealed
that optimal inhibition of PG synthesis is typically achieved
when ring A is substituted in the para-position with either a
chloride (e.g., 54) or methoxy group (e.g., 59). With respect to
ring B, comparison of 54, 68, 76, 79, 84, and 98 clearly suggests
that the presence of fluorine substituents is not detrimental, or
necessary, for inhibition of PG production. Evaluation of the
effect of different substitutions in the imidazole ring reveals
that, with the possible exception of compound 104, which
shows a >50% inhibition in the PGD2/PGE2 assay,
tetrasubstituted compounds (e.g., 45, 46, 85, 88) are generally
devoid of inhibitory activity against PG synthesis. Conversely,
1,5-diarylimidazole congeners with one substitution at either
C2 or C4 are generally active, with the presence of a substituent
at C4 being possibly preferred over the C2 position (cf. 62 with
63, 64 with 66, 84 with 87, and 92 with 93). Among
1,5-diarylimidazoles that are not substituted at C2 and C4,
although these compounds appear to be generally less active
than the corresponding compounds bearing a substituent at
C2 or C4, selected examples, such as 51, have been identified
that produce a near complete inhibition of the combined
PGD2/PGE2 synthesis in the RBL-1 cell assay when tested at 10 μM.
Inhibition of Leukotriene Biosynthetic Pathway.
Finally, evaluation of compound inhibitory activity in the
LTB4 assay revealed that whereas a number of substitutions
in the para-position of ring A appeared to be well tolerated,
the presence of a 2-chloro-pyridine (see 73 and 74) prevented
inhibition of LTB4 synthesis. In addition, similarly to what was
observed for the SAR of PGD2/PGE2 synthesis inhibition, the
fluorination of the B ring did not impact activity, as both
fluorinated (e.g., 59, 80 and 84) and nonfluorinated (e.g., 98)
congeners exhibit comparable inhibitory activity in the LTB4
assay. However, in contrast to what was observed for inhibitory
activity against PG synthesis, the choice of substituents
at C2 and/or C4 of the imidazole ring did not play a critical
role as examples of di- (e.g., 47), tri- (e.g., 89 and 90) and
tetra-substituted (e.g., 91) imidazoles were found to exhibit
comparable suppression of LTB4 synthesis in RBL-1 cells
at 10 μM.
Thus, in light of the observed elements of SAR for the three
biological targets, the particular substitution pattern decorating
the 1,5-diarylimidazole scaffold can result in compounds
with different activity profiles, including multitargeted activity
on MTs and/or eicosanoid biosynthesis (Figure 2). Selected
representative examples of multitargeted compounds were
Scheme 2a
aReagents and reaction conditions: (a) N-chlorosuccinimide, CHCl3,
60 °C, 16 h, 9−77% for monohalogenation at C4, 3−18% for mono-
halogenation at C2, and 2−20% for dihalogenation at C2/C4;
(b) LDA, methyliodide, THF, −20 °C to rt, 1.5 h, 2−48%;
(c) NaOMe, MeOH, THF, rt, 19 h, 33−97%; (d) LDA, ethyliodide,
THF, −20 °C to rt, 1.5 h, 35%.
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Table 1. Evaluation of Test Compounds as MT-Stabilizing Agents and Inhibitors of COX- and 5-LOX Pathways
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evaluated further to determine the IC50 values in the RBL-1 cell
assays and brain penetration (see Figure 3 and Table 2).
Moreover, the compounds in Table 2 were also examined with
improved LC/MS/MS methodologies for their ability to inhibit
the individual COX-derived products PGE2 and PGD2 as well
as a second 5-LOX-derived product, LTC4 (see Supporting
Information, Figure S1). Finally, two example compounds
underwent full concentration−response analyses in the AcTub
assay (see Supporting Information, Figure S2). Collectively,
these studies confirmed that all Table 2 compounds effectively
inhibited both COX and 5-LOX biosynthetic pathways with
multiple compounds exhibiting balanced multitargeted activity
in the low μM range. Finally, consistent with the relatively
small size of these molecules, these compounds appeared to be
generally brain-penetrant.
■ DISCUSSION
Although selected cholinesterase inhibitors and a single NMDA
receptor antagonist are approved for the treatment of AD, these
provide only a modest and temporary symptomatic improve-
ment in AD patients and thus far there have been no examples
of disease-modifying drug candidates for AD with demon-
strated efficacy in phase III clinical trials.43 This situation may
be due, at least in part, to the fact that several neuropathological
mechanisms are likely to provide potentially alternative or
redundant pathways to drive/sustain the neurodegenerative
process in AD. NSAIDs, for example, once attracted con-
siderable attention as potential candidates for AD treatment
due to promising results in a series of preclinical studies in
animal models with Aβ plaque pathology,44−48 coupled with
compelling retrospective epidemiological data indicating that
individuals who were on sustained regimens of COX-inhibiting
NSAIDs had reduced AD risk.45,49 A series of clinical trials with
different COX inhibitors, however, yielded mostly disappoint-
ing results.45,50−52 Although there may be multiple reasons
for the lack of efficacy in these clinical trials, including issues
with the particular candidate compounds used in the studies
and/or trials that were conducted in patient populations with
disease that was too advanced to respond to this therapeutic
approach, or who had dementia that was not due to underlying
AD pathology, another possible mechanistic explanation may
be that even if substantial COX inhibition is achieved within
the AD brain, this may not prevent the detrimental effects of
inflammatory LTs. Indeed, different studies have now shown
that these 5-LOX products are likely to contribute to Aβ plaque
pathology,8,18,20,21,23 and there is evidence that blocking COX
metabolism can lead to shunting of arachidonic acid to the
5-LOX pathway.53−55 Furthermore, it may be also argued that
any potential benefit of lowering Aβ production and plaque
pathology alone may be limited if tau pathology persists.
Indeed, a recent retrospective analysis of several late-stage AD
clinical trials, including the NSAIDs studies, concluded that
candidate therapeutics affecting one target alone may not be
likely to impact significantly disease progression,43 suggesting
that the evaluation and development of multitargeted approaches
for AD would be desirable.56 However, although different
examples of multitargeted constructs have been proposed as
experimental AD treatments, there have been only a few
reports57 of molecules that exhibit polypharmacology against
targets that are likely involved in tau and Aβ neuropathology.
Prior studies suggested that axonal transport deficits
associated with a loss of MTs and/or altered MT dynamics
in the axon of neurons comprise a key neuropathological step
of tauopathies and possibly other neurodegenerative diseases.24
As part of our ongoing efforts to develop brain-penetrant
MT-stabilizing agents as potential treatments for these diseases,
we identified selected heterocyclic compounds that are not
derived from natural products, as exemplified here by
triazolopyrimidine 10758 (Table 1), which exhibit a promising
combination of MT-stabilizing activity and brain penetra-
tion.37,39 Among compound classes that are structurally and
functionally related to the triazolopyrimidines are a series of
1,5-diarylimidazoles.35 Like the triazolopyrimidines, these
imidazoles are found to promote MT polymerization in cell-
free assays and exhibit relatively potent and broad-spectrum
fungicidal activity.35 Furthermore, considering that these
tricyclic compounds exhibit structural similarities with known
NSAIDs, they may be considered as possible starting points in
the development of small molecules that could concurrently
stabilize MTs and lower eicosanoid production. Given that MT
dynamics are believed to be affected in AD and other neuro-
degenerative disorders,24,59 and considering the involvement of
Table 1. continued
aInhibition of COX pathway was determined by monitoring via LC/MS/MS analyses the combined production of COX-derived PGD2 and PGE2 in
RBL-1 cells upon stimulation with arachidonic acid in the presence or absence of test compounds, with all samples run in at least triplicate.
bInhibition of 5-LOX pathway was determined by monitoring via LC/MS/MS analyses the production of 5-LOX-derived LTB4 in RBL-1 cells upon
stimulation with arachidonic acid in the presence or absence of test compounds, with all samples run in at least triplicate. cMT-stabilizing activity in
QBI-293 cells was determined by monitoring via ELISA the changes in acetylated α-tubulin levels relative to vehicle treatment in response to 4 h
treatment with 1 and 10 μM test compounds, with all samples run in at least triplicate. The compound concentrations causing a significant change in
AcTub are listed, along with the fold-change in AcTub. dRelative changes in total α-tubulin, as determined by tubulin ELISA, in response to
1 and 10 μM compound treatment, with all samples run in at least triplicate. The compound concentrations causing a significant change in a-Tub are
listed, along with the fold-change in a-Tub. §, Compound tested at 10 nM.∧, Previously published data.39 *, P < 0.05. **, P < 0.01 compared with
vehicle (DMSO)-treated controls as determined using an two-tailed unpaired t test. NS, not significant. ND, not determined.
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both COX- and 5-LOX derived eicosanoids in AD and likely
other neurodegenerative diseases, a normalization of axonal MT
dynamics, combined with a suppression of eicosanoid pro-
duction, may provide a potential multitargeted strategy to
mitigate concurrent disease mechanisms in AD and other
neurodegenerative conditions.
Our multitargeted structure−activity relationship (SAR) studies
began with the observation that selected examples from the
previously reported fungicidal imidazoles,35 such as 2, exhibit
evidence of activity both as MT-stabilizing agents and inhibitors
of eicosanoid biosynthesis in vitro, suggesting a potentially
significant overlap between the pharmacophore of these
MT-stabilizing imidazoles and that of NSAIDs such as 3
(COX-1 inhibitor33). On the basis of these initial findings,
and taking into consideration prior SAR studies35 that defined
a set of preferred substitutions on the imidazole ring that are
Figure 2. Summary of SARs (top) and representative structures exemplifying the different activity profiles exhibited by the 1,5-diarylimidazoles
(bottom).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b00475
J. Med. Chem. 2017, 60, 5120−5145
5130
generally important for fungicidal activity, and thus presumably
for MT-stabilizing activity, we focused on evaluating whether
changes in the substitution patterns of 1,5-diarylimidazoles may
result in compounds with improved and balanced multitargeted
activities. In particular, given that optimal broad-spectrum
fungicidal activity is typically achieved with tetrasubstituted
imidazoles (e.g., 2) and other related congeners that comprise a
4-chlorophenyl group at N1, a chlorine atom in position 4, and
a di- or trifluorinated phenyl group in position 5, we focused
primarily on evaluating (a) mono- and disubstitutions in the
A ring, (b) chloro- and/or alkyl-substitutions in positions 2
and/or 4 of the imidazole ring, and (c) the effect of varying the
degree and pattern of fluorination in the B ring. As shown in
Table 1, these studies demonstrated that relatively small changes
in the substitution pattern of 1,5-diarylimidazoles can have
profound effect in the activity profile of these molecules and
ultimately led to the identification of several compounds with
MT-stabilizing activity and inhibitory activity against the COX
and/or 5-LOX pathways (see Table 2). Furthermore, with
respect to the MT-stabilizing activity, our studies suggest that
like the triazolopyrimidines, MT-stabilizing 1,5-diarylimidazoles
are likely to affect MT structures in different ways depending on
the particular substitution pattern. In the case of triazolopyr-
imidines, it was suggested that congeners bearing an alkoxy side
chain in the fluorinated phenyl ring (e.g., 108) typically produce
an unusual cellular phenotype that is characterized by a bell-
shaped concentration−response relationship in the AcTub
assay and proteasome-dependent degradation of α- and
β-tubulin.39 Interestingly, a similar type of observation is seen
with the 1,5-diarylimidazoles, as all MT-active compounds
bearing an alkoxy substituent in ring B (i.e., 2, 58, 95−97,
Table 1) produce a loss in α-tubulin at compound concentra-
tions that are required to observe an increase in AcTub.
However, our results with the 1,5-diarylimidazoles clearly
suggest that the substitution pattern of ring B may not be the
only determining factor in whether α-tubulin is affected, as
other substitutions in the A and C ring appear to play a role
(e.g., compare 29 with 30, and 54 with 73, Table 1). As was
noted for the triazolopyrimidines,39 compounds found to cause
a reduction in total tubulin may not be desirable for neuro-
degenerative diseases as this effect would be expected to
ultimately compromise rather than restore axonal MT function.
Conversely, certain multitargeted congeners, including examples
listed in Table 2 that do not appear to reduce total α-tubulin
levels at concentrations that increase AcTub, may be more
promising candidates for tauopathy treatment. Further studies,
however, will be necessary to confirm that these compounds can
produce beneficial effects in an animal model of tau pathology,
as observed previously with MT-stabilizing natural products like
paclitaxel,60 epothilone D, and dictyostatin.4−7
With respect to the ability of these compounds to act as
inhibitors of the COX and/or 5-LOX pathways, although the
IC50 values in the COX biosynthetic pathway assay are much
higher than the IC50 of COX inhibitor 3 (i.e., ∼1 nM), the
activity level displayed by these molecules is closely comparable
to that of the over-the-counter drug, ibuprofen (105; Table 1
and Figure 3). Unlike 105 or 3, however, these multitargeted
1,5-diarylimidazoles (e.g., 79, see Table 2 and Figure 3) exhibit
inhibition activity against the leukotriene biosynthetic pathway,
while other derivatives (Table 2) are also capable of affecting
MT stability in vitro, with several examples (e.g., 68, 70, 87)
exhibiting relatively balanced multitargeted activity. Moreover,
an evaluation of the brain penetration of these molecules
revealed that these multitargeted prototypes are generally capable
of reaching significant brain concentrations after peripheral
administration, suggesting that compounds of this type may be
appropriate for further evaluation in the context of CNS diseases.
Taken together, these results indicate that these 1,5-diary-
limidazoles comprise a promising scaffold for the evaluation of
CNS-directed multitargeted strategies that either focus on a
concurrent inhibition of COX and 5-LOX biosynthetic pathways
or on a combined stabilization of MTs and inhibition of
eicosanoid production.
Figure 3. Representative dose−response curves in the RBL-1 cell assays. Samples were run in triplicate at each concentration, with the error bars
representing standard error of the mean.
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Table 2. Further Evaluation of Test Compounds with Multitargeted Activity as MT-Stabilizing Agents and/or Inhibitors of COX
and 5-LOX Pathways
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■ CONCLUSIONS
Starting from a series of 1,5-diarylimidazoles with reported
MT-stabilizing activity and structural similarities with known
NSAIDs, the SAR studies reported here led to the identification
of a series of congeners that exhibit balanced low μM in vitro
activity as MT-stabilizing agents and/or inhibitors of the
COX and 5-LOX pathways. Given that prior preclinical studies
demonstrated that MT stabilization in neurons is a promising
therapeutic strategy to treat tau-mediated neurodegeneration,
combined with the considerable body of evidence implicating
eicosanoids in Aβ plaque pathology, the balanced polypharma-
cology and brain penetration displayed by these compounds
suggest that they are promising research tools as well as
possible lead structures to investigate multitargeted therapeutic
approaches for AD.
■ EXPERIMENTAL SECTION
Materials and Methods. All solvents were reagent grade. All
reagents were purchased from Aldrich or Acros and used as received.
Thin layer chromatography (TLC) was performed with 0.25 mm
E. Merck precoated silica gel plates. Silica gel column chromatography
was performed with silica gel 60 (particle size 0.040−0.062 mm)
supplied by Silicycle and Sorbent Technologies. TLC spots were
detected by viewing under a UV light. Melting points (mp) were
acquired on a Thomas−Hoover apparatus and are uncorrected.
Infrared (IR) spectra were recorded on a Jasco model FT/IR-480
Plus spectrometer. Proton (1H) and carbon (13C) NMR spectra were
recorded on a Bruker AMX-500 spectrometer. Chemical shifts were
reported relative to solvents. High-resolution mass spectra were
measured at the University of Pennsylvania Mass Spectrometry
Center on either a VG Micromass 70/70H or VG ZAB-E spectrometer.
Single-crystal X-ray structure determinations were performed at the
University of Pennsylvania with an Enraf Nonius CAD-4 diffractometer.
Analytical reverse-phase (Sunfire C18; 4.6 mm × 50 mm, 5 mL) high-
performance liquid chromatography (HPLC) was performed with a
Waters binary gradient module 2525 equipped with Waters 2996 PDA
and Waters micromass ZQ. All samples were analyzed employing a
linear gradient from 10% to 90% of CH3CN in water over 8 min and
flow rate of 1 mL/min, and unless otherwise stated, the purity level was
>95%. Preparative reverse-phase HPLC purifications were performed
on a Gilson instrument (i.e., Gilson 333 pumps, a 215 liquid handler,
845Z injection module, and PDA detector) employing Waters SunFire
preparative C18 OBD columns (5 μm 19 mm × 50 mm or 19 mm ×
100 mm). Purifications were carried out employing a linear gradient
from 10% to 90% of CH3CN in water for 15 min with a flow rate of
20 mL/min. Unless otherwise stated, all final compounds were found to
be >95% pure as determined by HPLC/MS and NMR.
General Procedure A for the Synthesis of Imines. A solution of
aniline (1 equiv) and benzaldehyde (1 equiv) in toluene (0.2 M) was
heated at 110 °C in a Dean−Stark apparatus for 4 days. The reaction
mixture was then cooled and evaporated in vacuo to obtain the
title compound, which was used in the next step without further
purification.
General Procedure B for the Synthesis of Imines. To a solution of
a primary amine (1 equiv) in anhydrous Et2O (0.3 M) in the presence
of molecular sieves (4 Å, 1.6 mm pellets, 7 g/mmol) was added an
aldehyde (1 equiv) according to the Taguchi’s method. The mixture
was heated and stirred at 30 °C for 48 h. Molecular sieves were then
removed by filtration, and the solvent was evaporated in vacuo to
afford the desired imine in quantitative yields.
General Procedure C for the Synthesis of Imidazoles. To a
solution of imine (1 equiv) in a mixture of DMF (0.26 M) and
1,2-dimethoxyethane (0.32 M) were added toluenesulfonylmethyl
isocyanide (1.5 equiv) and anhydrous K2CO3 (2.08 equiv). The
reaction mixture was heated for 16 h at 100 °C, then cooled to rt,
filtered, and evaporated in vacuo. The resulting material was adsorbed
on Celite 545 AW and purified by silica gel column chromatography to
obtain the desired compound.
General Procedure D for the Synthesis of 4-Alkylated Imidazoles.
To a solution of imine (1 equiv) in a mixture of DMF (0.14 M) and
1,2-dimethoxyethane (0.17 M) were added 1-((1-isocyanoethyl)-
sulfonyl)-4-methylbenzene (1.5 equiv) and anhydrous K2CO3
(2.08 equiv). The reaction mixture was heated for 16 h at 100 °C,
then cooled to rt, filtered through a pad of Celite 545 AW, and
evaporated in vacuo. The resulting material was purified by silica gel
column chromatography to obtain the desired compound.
General Procedure E for the Mono- and Dichlorination of 1,5-
Diarylimidazoles. To a solution of imidazole (1 equiv) in CHCl3
(0.16 M) was added N-chlorosuccinimide (1.06 equiv). The reaction
mixture was heated at 60 °C for 16 h, then cooled to rt and diluted
with EtOAc. The organic layer was washed with brine (×3), dried over
MgSO4, filtered, and evaporated in vacuo. Purification via silica gel column
chromatography furnished the mono- and dichlorinated imidazoles.
General Procedure F for Alkylation of 1,5-Diarylimidazoles. To a
solution of diisopropylamine (1.5 equiv) in THF (0.3 M) at −20 °C
was added n-BuLi (2.5 M in hexanes, 1.5 equiv), and the mixture was
stirred for 10 min. A solution of imidazole (1 equiv) in THF (0.15 M)
was added, and after stirring for 30 min, methyl iodide or ethyl iodide
(3 equiv) was added. The mixture was stirred for 30 min at −20 °C
and for 30 min at rt. H2O was then added to the reaction mixture. The
aqueous phase was extracted with EtOAc, and the combined organic
layers were washed with brine (×3), dried over MgSO4, filtered, and
concentrated in vacuo. Purification via silica gel column chromatog-
raphy furnished the desired alkylated imidazoles.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methoxyphenyl)-
2-methyl-1H-imidazole (2). To a solution of 4-chloro-1-(4-
chlorophenyl)-2-methyl-5-(2,4,6-trifluorophenyl)-1H-imidazole
(0.004 g, 0.011 mmol) in THF (0.011 mL) at 0 °C was added a 30%
sodium methoxide solution in MeOH (0.007 mL). The reaction
mixture was stirred for 19 h at rt, then quenched with an aqueous
ammonium chloride solution and extracted with EtOAc (3×). The
combined organic layers were dried (MgSO4), filtered, and con-
centrated in vacuo. The crude products were purified by preparative
reverse-phase HPLC to obtain the title compound as a white solid
(0.004 g, 0.011 mmol, 97% yield). 1H NMR (500 MHz, CDCl3) δ
7.40 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 2H), 6.41 (d, J = 9.1 Hz,
2H), 3.78 (s, 3H), 2.41 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ
163.04 (t, J = 14.0 Hz), 161.61 (dd, J = 249.5, 8.9 Hz), 145.57, 136.11,
133.46, 130.11, 129.90, 128.65, 128.38, 127.63, 117.32, 98.38 (d, J =
28.0 Hz), 96.57 (t, J = 20.8 Hz), 56.09, 13.37 ppm. IR (KBr) ν 2962,
2928, 2852, 1646, 1575, 1494, 1448, 1152 cm−1. HRMS (ES+)
calculated for C17H13Cl2F2N2O [M + H]
+ 369.0373, found 369.0374.
(E)-N-(4-Chlorophenyl)-1-(2,4,6-trifluorophenyl)methanimine (5).
Following synthetic procedure A using 4-chloroaniline (0.829 g,
6.50 mmol) and 2,4,6-trifluorobenzaldehyde (1.04 g, 6.50 mmol),
the title compound was obtained as a brown solid (1.75 g, 6.49 mmol,
99% yield). 1H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 7.32 (app d,
J = 6.7 Hz, 2H), 7.12 (app d, J = 6.8 Hz, 2H), 6.73 (m, 2H) ppm.
(E)-N-(4-Methoxyphenyl)-1-(2,4,6-trifluorophenyl)methanimine
(6). Following synthetic procedure A using 4-methoxyaniline (0.370 g,
3.00 mmol) and 2,4,6-trifluorobenzaldehyde (0.480 g, 3.00 mmol), the
title compound was obtained as a brown solid (0.814 g, 3.07 mmol,
Table 2. continued
aAll concentration−response analyses were conducted at multiple concentrations with triplicate samples per concentration. bThe change in AcTub
was assessed as described in Table 1. #, Study conducted after a 5 mg/kg i.p. injection of test compound. ∧, Study conducted after a 2 mg/kg i.p.
injection of test compound with drug concentrations adjusted proportionally upward to allow comparison to 5 mg/kg doses. ND, not determined.
NS, not significant. ± errors represent standard deviations. All analyses were conducted with groups of three mice.
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99% yield). 1H NMR (500 MHz, CDCl3) δ 8.59 (s, 1H), 7.25−7.22
(m, 2H), 6.97−6.90 (m, 2H), 6.81−6.72 (m, 2H), 3.84 (s, 3H) ppm.
(E)-N-(4-Chlorophenyl)-1-(2,6-difluoro-3-methylphenyl)-
methanimine (7). Following synthetic procedure A using 4-chloro-
aniline (0.383 g, 3 mmol) and 2,6-difluoro-3-methylbenzaldehyde
(0.377 mL, 3 mmol), the title compound was obtained as a brown
solid (0.781 g, 2.94 mmol, 98% yield). 1H NMR (500 MHz, CDCl3) δ
8.63 (s, 1H), 7.36 (app d, J = 8.2 Hz, 2H), 7.25 (app q, J = 7.6 Hz,
1H), 7.17 (app d, J = 8.0 Hz, 2H), 6.89 (app t, J = 9.2 Hz, 1H), 2.28
(s, 3H) ppm.
(E)-1-(3-Chloro-2,6-difluorophenyl)-N-(4-chlorophenyl)-
methanimine (8). Following synthetic procedure A using 4-chloro-
aniline (0.383 g, 3 mmol) and 3-chloro-2,6-difluorobenzaldehyde
(0.530 g, 3 mmol), the title compound was obtained as a brown solid
(0.850 g, 2.97 mmol, 99% yield). 1H NMR (500 MHz, CDCl3) δ 8.60
(s, 1H), 7.47 (td, J = 8.4, 5.5 Hz, 1H), 7.37 (app d, J = 8.5 Hz, 2H),
7.17 (app d, J = 8.5 Hz, 2H), 7.00−6.96 (m, 1H) ppm. 13C NMR
(126 MHz, CDCl3) δ 159.87 (dd, J = 390.8, 5.6 Hz), 157.80 (dd, J =
393.2, 5.6 Hz), 150.87, 150.42, 132.72 (d, J = 10.3 Hz), 132.65,
129.47, 122.29, 117.77 (dd, J = 18.0, 3.9 Hz), 115.03 (t, J = 12.9 Hz),
112.80 (dd, J = 23.0, 4.4 Hz) ppm.
(E)-1-(3-Bromo-2,6-difluorophenyl)-N-(4-chlorophenyl)-
methanimine (9). Following synthetic procedure A using 4-chloro-
aniline (0.383 g, 3 mmol) and 3-bromo-2,6-difluorobenzaldehyde
(0.663 g, 3 mmol), the title compound was obtained as a brown solid
(0.971 g, 2.94 mmol, 98% yield). 1H NMR (500 MHz, CDCl3) δ 8.59
(s, 1H), 7.61 (dd, J = 14.2, 7.6 Hz, 1H), 7.36 (app d, J = 8.5 Hz, 2H),
7.17 (app d, J = 8.4 Hz, 2H), 6.93 (t, J = 9.2 Hz, 1H) ppm.
(E)-N-(4-Chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine
(10). Following synthetic procedure A using 4-chloro-aniline (0.383 g,
3 mmol) and 2,3,6-trifluorobenzaldehyde (0.337 mL, 3 mmol), the
title compound was obtained as a brown solid (0.778 g, 2.88 mmol,
96% yield). 1H NMR (500 MHz, CDCl3) δ 8.58 (s, 1H), 7.34 (app d,
J = 8.3 Hz, 2H), 7.26−7.20 (m, 1H), 7.16 (app d, J = 8.2 Hz, 2H), 6.92
(app t, J = 9.0 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.28,
156.26, 150.76, 150.19, 148.36−148.23 (m), 146.34 (dd, J = 12.5,
3.6 Hz), 132.51, 129.30, 122.18, 119.33 (dd, J = 19.4, 10.4 Hz), 115.07
(dd, J = 14.2, 9.0 Hz), 111.42 (dt, J = 24.4, 5.3 Hz) ppm.
(E)-N-(4-Chloro-3-fluorophenyl)-1-(2,3,6-trifluorophenyl)-
methanimine (11). Following synthetic procedure A using 4-chloro-3-
fluoroaniline (0.437 g, 3 mmol) and 2,3,6-trifluorobenzaldehyde
(0.337 mL, 3 mmol), the title compound was obtained as a brown
solid (0.846 g, 2.94 mmol, 98% yield).
(E) -N-(6-Chloropyr id in-3-yl ) -1-(2 ,4 ,6-tr ifluorophenyl )-
methanimine (12). Following synthetic procedure A using
6-chloropyridin-3-amine (0.385 g, 3 mmol) and 2,4,6-trifluorobenzal-
dehyde (0.480 g, 3 mmol), the title compound was obtained as a
brown solid (0.786 g, 2.90 mmol, 97% yield).
(E)-N-(4-Chlorophenyl)-1-(4-fluorophenyl)methanimine (13). Fol-
lowing synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol)
and 4-fluorobenzaldehyde (0.322 mL, 3 mmol), the title compound
was obtained as a brown solid (0.687 g, 2.94 mmol, 98% yield).
(E)-N-(4-Chloro-2-fluorophenyl)-1-(2,6-difluorophenyl)-
methanimine (14). Following synthetic procedure A using 4-chloro-2-
fluoroaniline (0.437 g, 3 mmol) and 2,6-difluorobenzaldehyde (0.426 g,
3 mmol), the title compound was obtained as a brown solid (0.768 g,
2.85 mmol, 95% yield).
(E)-N-(4-Chlorophenyl)-1-(2,5-difluorophenyl)methanimine (15).
Following synthetic procedure A using 4-chloro-aniline (0.383 g,
3 mmol) and 2,5-difluorobenzaldehyde (0.326 mL, 3 mmol), the title
compound was obtained as a brown solid (0.698 g, 2.77 mmol, 93%
yield). 1H NMR (500 MHz, CDCl3) δ 8.66 (s, 1H), 7.84 (dt, J = 7.6,
4.2 Hz, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H),
7.14−7.06 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 159.88,
157.92 (dd, J = 7.7, 1.9 Hz), 152.39 (d, J = 1.2 Hz), 149.67, 132.37,
131.65 (d, J = 16.8 Hz), 129.36, 129.11 (dd, J = 51.2, 13.4 Hz), 125.04
(dd, J = 11.3, 7.8 Hz), 122.40 (d, J = 19.7 Hz), 119.85 (dd, J = 24.9,
9.0 Hz), 117.27 (dd, J = 24.0, 8.3 Hz), 113.64 (dd, J = 25.1, 2.9 Hz) ppm.
(E)-1-(2,6-Difluorophenyl)-N-(4-(trifluoromethoxy)phenyl)-
methanimine (16). Following synthetic procedure A using
4-(trifluoromethoxy)aniline (0.531 g, 3.00 mmol) and 2,6-difluor-
obenzaldehyde (0.426 g, 3.00 mmol), the title compound was obtained
as a brown liquid (1.034 g, 3.43 mmol, 99% yield). 1H NMR
(500 MHz, CDCl3) δ 8.65 (s, 1H), 7.46−7.39 (m, 1H), 7.26−7.22
(m, 4H), 7.01 (t, J = 8.6 Hz, 2H) ppm.
(E)-N-(4-Chlorophenyl)-1-(2,6-difluorophenyl)methanimine (17).
Following synthetic procedure A using 4-chloroaniline (0.829 g,
6.50 mmol) and 2,6-difluorobenzaldehyde (0.924 g, 6.50 mmol), the
title compound was obtained as a brown liquid (1.62 g, 6.45 mmol,
99% yield). 1H NMR (500 MHz, CDCl3) δ 8.64 (s, 1H),
7.46−7.40 (m, 1H), 7.40−7.34 (m, 2H), 7.20−7.14 (m, 2H), 7.04−
6.96 (m, 2H) ppm.
(E)-N-(4-(Trifluoromethoxy)phenyl)-1-(2,3,6-trifluorophenyl)-
methanimine (18). Following synthetic procedure A using
4-(trifluoromethoxy)aniline (0.531 g, 3.00 mmol) and 2,3,6-trifluor-
obenzaldehyde (0.480 g, 3.00 mmol), the title compound was obtained
as a brown solid (1.08 g, 3.47 mmol, 99% yield). 1H NMR (500 MHz,
CDCl3) δ 8.62 (s, 1H), 7.45−7.25 (m, 2H), 7.27−7.22 (m, 2H),
7.20−7.11 (m, 1H), 7.02−6.93 (m, 1H) ppm.
(E)-N-(4-Chlorophenyl)-1-(2,6-difluoro-4-methylphenyl)-
methanimine (19). Following synthetic procedure A using
4-chloroaniline (0.157 g, 1.23 mmol) and 2,6-difluoro-4-methylben-
zaldehyde (0.192 g, 3 mmol), the title compound was obtained as a
brown solid (0.183 g, 0.69 mmol, 56% yield). 1H NMR (500 MHz,
CDCl3) δ 8.59 (s, 1H), 7.36 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 8.2 Hz,
2H), 6.82 (d, J = 10.1 Hz, 2H), 2.40 (s, 3H) ppm.
(E)-N-(4-Chlorophenyl)-1-(2,6-difluoro-3-methoxyphenyl)-
methanimine (20). Following synthetic procedure A using
4-chloroaniline (0.383 g, 3.00 mmol) and 2,6-difluoro-3-methox-
ybenzaldehyde (0.468 g, 3.00 mmol), the title compound was obtained
as a brown solid (0.745 g, 2.64 mmol, 88% yield). 1H NMR
(500 MHz, CDCl3) δ 8.63 (s, 1H), 7.39−7.32 (m, 2H), 7.20−7.11
(m, 2H), 7.07−6.98 (m, 1H), 6.96−6.87 (m, 1H), 3.90 (s, 3H) ppm.
(E)-N-(4-Chlorophenyl)-1-phenylmethanimine (21). Following
synthetic procedure A using 4-chloroaniline (0.383 g, 3.00 mmol)
and benzaldehyde (0.318 g, 3.00 mmol), the title compound was
obtained as a brown solid (0.702 g, 3.25 mmol, 99% yield). 1H NMR
(500 MHz, CDCl3) δ 8.44 (s, 1H), 7.96−7.87 (m, 2H), 7.57−7.45
(m, 3H), 7.36 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.3 Hz, 2H) ppm.
(E)-N-(4-Chlorophenyl)-1-(4-methoxyphenyl)methanimine (22).
Following synthetic procedure B using 4-chloroaniline (0.765 g,
6.00 mmol) and 4-methoxybenzaldehyde (0.817 g, 6.00 mmol), the
title compound was obtained as a yellow solid (1.370 g, 5.58 mmol,
93% yield). 1H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H), 7.84 (d, J =
8.4 Hz, 2H), 7.37−7.31 (m, 2H), 7.13 (d, J = 8.5 Hz, 2H), 6.98 (d, J =
8.4 Hz, 2H), 3.87 (s, 3H) ppm.
(E)-1-(2,6-Difluorophenyl)-N-phenylmethanimine (23). Following
synthetic procedure B using aniline (0.559 g, 6.00 mmol) and
2,6-difluorobenzaldehyde (0.853 g, 6.00 mmol), the title compound
was obtained as a yellow liquid (0.637 g, 2.93 mmol, 49% yield).
1H NMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 7.44−7.34 (m, 3H),
7.26−7.19 (m, 3H), 7.02−6.95 (m, 2H) ppm.
(E)-N-(2-Chlorophenyl)-1-(2,6-difluorophenyl)methanimine (24).
Following synthetic procedure B using 2-chloroaniline (0.765 g,
6.00 mmol) and 2,6-difluorobenzaldehyde (0.853 g, 6.00 mmol), the
title compound was obtained as a yellow liquid (1.41 g, 5.58 mmol,
93% yield). 1H NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 7.49−7.39
(m, 2H), 7.32−7.27 (m, 1H), 7.20−7.14 (m, 1H), 7.06−6.98 (m, 3H)
ppm.
1-(4-Chlorophenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (25).
Following synthetic procedure C using (E)-N-(4-chlorophenyl)-1-
(2,4,6-trifluorophenyl)methanimine (0.865 g, 3.21 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40)
afforded the title compound as a white powder (0.429 g, 1.39 mmol,
43% yield). 1H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H), 7.39−7.36
(m, 2H), 7.35 (s, 1H), 7.13−7.10 (m, 2H), 6.71−6.65 (m, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 163.14 (dt, J = 252.4, 15.3 Hz),
160.75 (ddd, J = 251.5, 14.9, 8.7 Hz), 138.95, 134.96, 134.41, 132.41,
129.76, 125.94, 119.16, 103.78 (td, J = 20.0, 4.6 Hz), 100.97−100.52
(m) ppm. IR (KBr) ν 3114, 3095, 3043, 2922, 1692, 1644, 1600, 1562,
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1466, 1438, 1322, 1130 cm−1. HRMS (ES+) calculated for
C15H9ClF3N2 [M + H]
+ 309.0401, found 309.0339.
1-(4-Methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (26).
Following synthetic procedure C using (E)-N-(4-methoxyphenyl)-1-
(2,4,6-trifluorophenyl)methanimine (0.814 g, 3.07 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 60:40) afforded
the title compound as an orange solid (0.065 g, 0.214 mmol, 7% yield).
1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H), 7.25 (s, 1H), 7.09−7.04
(m, 2H), 6.88−6.83 (m, 2H), 6.66−6.59 (m, 2H), 3.79 (s, 3H) ppm.
13C NMR (126 MHz, CDCl3) δ 163.05 (dt, J = 251.4, 15.1 Hz), 160.93
(ddd, J = 251.1, 14.8, 8.6 Hz), 159.50, 139.30, 131.76, 129.27, 126.21,
119.50, 114.58, 104.15 (td, J = 20.4, 4.9 Hz), 101.30−99.76 (m),
55.61 ppm. IR (KBr) ν 3102, 3008, 2935, 2840, 1689, 1644, 1599, 1564,
1515, 1489, 1465, 1439, 1301, 1250, 1172, 1123, 1033 cm−1. HRMS
(ES+) calculated for C16H12F3N2O [M + H]
+ 309.0902, found 309.0908.
1-(4-Chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1H-imida-
zole (27). Following synthetic procedure C using (E)-N-(4-
chlorophenyl)-1-(2,6-difluoro-3-methylphenyl)methanimine (0.399 g,
1.5 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 80:20 to 20:80) afforded the title compound as a
yellow solid (0.327 g, 1.07 mmol, 72% yield). 1H NMR (500 MHz,
CDCl3) δ 7.81 (s, 1H), 7.31 (t, J = 7.6 Hz, 3H), 7.15−7.08 (m, J =
15.1, 7.5 Hz, 3H), 6.75 (t, J = 8.6 Hz, 1H), 2.18 (s, 3H) ppm. MS
(ES+) calculated for C16H11ClF2N2 [M + H]
+ 305.07, found 305.03.
5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imidazole
(28). Following synthetic procedure C using (E)-1-(3-chloro-2,6-
difluorophenyl)-N-(4-chlorophenyl)methanimine (0.429 g, 1.5 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
100:0 to 60:40) afforded the title compound as a white solid (0.298 g,
0.916 mmol, 61% yield). 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J =
0.5 Hz, 1H), 7.32−7.27 (m, 4H), 7.06−7.04 (m, 2H), 6.78 (td, J = 8.7,
1.4 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.27 (dd, J =
251.2, 4.4 Hz), 155.38 (dd, J = 252.0, 6.3 Hz), 138.97, 134.65, 134.11,
132.45, 130.90, 130.83, 129.57, 125.53, 119.00, 116.96 (dd, J = 18.6,
4.2 Hz), 112.05 (dd, J = 23.5, 4.1 Hz), 108.51 (t, J = 20.1 Hz) ppm.
MS (ES+) calculated for C15H9Cl2F2N2 [M + H]
+ 325.01, found 324.93.
5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1H-
imidazole (29). Following synthetic procedure D using (E)-1-(3-
chloro-2,6-difluorophenyl)-N-(4-chlorophenyl)methanimine (0.800 g,
2.80 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 65:35) afforded the title compound as an orange
solid (0.433 g, 1.28 mmol, 46% yield). 1H NMR (500 MHz, CDCl3) δ
7.72 (s, 1H), 7.37 (ddd, J = 9.0, 8.0, 5.6 Hz, 1H), 7.34−7.27 (m, 2H),
7.08−7.01 (m, 2H), 6.84 (ddd, J = 9.0, 8.2, 1.8 Hz, 1H), 2.20 (s, 3H)
ppm. 13C NMR (126 MHz, CDCl3) δ 158.82 (dd, J = 250.6, 4.6 Hz),
155.87 (dd, J = 251.8, 6.6 Hz), 140.71, 138.02, 135.11, 134.20, 131.25
(d, J = 9.6 Hz), 129.79, 125.77, 117.22 (dd, J = 18.7, 4.2 Hz), 115.41,
112.29 (dd, J = 23.6, 4.3 Hz), 109.12 (t, J = 20.3 Hz), 13.48 ppm.
IR (KBr) ν 3077, 3036, 2960, 2925, 1625, 1568, 1498, 1477, 1453,
1352, 1282, 1269, 1218, 1091, 1003 cm−1. HRMS (ES+) calculated for
C16H11Cl2F2N2 [M + H]
+ 339.0267, found 339.0273.
2-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-
methyl-1H-imidazole (30). Following synthetic procedure E using
5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1H-imi-
dazole (0.150 g, 0.442 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 80:20) afforded the title compound
as a white solid (0.071 g, 0.190 mmol, 43% yield). 1H NMR
(500 MHz, CDCl3) δ 7.39−7.31 (m, 3H), 7.14−7.06 (m, 2H),
6.86−6.75 (m, 1H), 2.17 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3)
δ 158.94 (dd, J = 250.9, 4.3 Hz), 156.02 (dd, J = 252.1, 6.2 Hz),
139.23, 135.37, 133.53 (d, J = 11.2 Hz), 131.74 (d, J = 9.8 Hz), 129.85,
129.61, 128.57, 117.71, 117.16 (dd, J = 18.3, 3.5 Hz), 112.23 (dd, J =
23.6, 4.3 Hz), 108.57 (t, J = 20.1 Hz), 13.43 ppm. IR (KBr) ν 3074,
2924, 2848, 1627, 1572, 1494, 1474, 1455, 1388, 1283, 1218, 1092,
1007 cm−1. HRMS (ES+) calculated for C16H10Cl3F2N2 [M + H]
+
372.9878, found 372.9874.
5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-2,4-dimethyl-
1H-imidazole (31). Following synthetic procedure F using 5-(3-
chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1H-imidazole
(0.050 g, 0.147 mmol), purification by silica gel column chromatog-
raphy (hexanes/EtOAc 60:40) afforded the title compound as a
orange solid (0.029 g, 0.082 mmol, 56% yield). 1H NMR (500 MHz,
CDCl3) δ 7.34−7.29 (m, 2H), 7.31−7.26 (m, 1H), 7.03 (d, J = 8.4 Hz,
2H), 6.82−6.74 (m, 1H), 2.29 (s, 3H), 2.14 (s, 3H) ppm. 13C NMR
(126 MHz, CDCl3) δ 158.99 (dd, J = 249.9, 4.9 Hz), 156.01 (dd, J =
251.2, 6.6 Hz), 146.28, 138.04, 135.07, 134.66, 130.99 (d, J = 9.7 Hz),
129.62, 128.34, 116.96 (dd, J = 19.0, 3.9 Hz), 115.69, 112.05 (dd, J =
23.9, 4.3 Hz), 109.60 (t, J = 20.7 Hz), 14.04, 13.13 ppm. IR (KBr)
ν 3052, 2962, 2922, 2849, 1693, 1629, 1593, 1571, 1495, 1474,
1402, 1266, 1218, 1092, 1004 cm−1. HRMS (ES+) calculated for
C17H13Cl2F2N2 [M + H]
+ 353.0424, found 353.0413.
5-(3-Bromo-2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imidazole
(32). Following synthetic procedure C using (E)-1-(3-bromo-2,6-
difluorophenyl)-N-(4-chlorophenyl)methanimine (0.495 g, 1.5 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
100:0 to 60:40) afforded the title compound as a yellow solid (0.450 g,
1.22 mmol, 82% yield). 1H NMR (500 MHz, CDCl3) δ 7.83 (s, 1H),
7.53 (ddd, J = 8.8, 7.7, 5.8 Hz, 1H), 7.37−7.34 (m, 3H), 7.12−7.11
(m, 2H), 6.82 (td, J = 8.7, 1.4 Hz, 1H) ppm. MS (ES+) calculated for
C15H9BrClF2N2 [M + H]
+ 368.96, found 368.98.
1-(4-Chlorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (33).
Following synthetic procedure C using (E)-N-(4-chlorophenyl)-1-
(2,3,6-trifluorophenyl)methanimine (0.405 g, 1.5 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40)
afforded the title compound as a brown solid (0.350 g, 1.13 mmol,
76% yield). 1H NMR (500 MHz, CDCl3) δ 7.80 (s, 1H), 7.34−7.31
(m, 3H), 7.15−7.11 (m, J = 9.0, 5.0 Hz, 1H), 7.09 (d, J = 8.6 Hz, 2H),
6.82−6.78 (m, 1H) ppm. MS (ES+) calculated for C15H8ClF3N2
[M + H]+ 309.04, found 309.18.
1-(4-Chlorophenyl)-2-methyl-5-(2,3,6-trifluorophenyl)-1H-imida-
zole (34). To a solution of diisopropylamine (0.02 mL, 0.146 mmol,
1.5 equiv) in THF (0.3 M) at −20 °C was added n-BuLi (2.5 M in
hexanes, 0.06 mL, 0.146 mmol, 1.5 equiv), and the mixture was stirred
for 10 min. A solution of 1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-
1H-imidazole (0.030 g, 0.097 mmol, 1 equiv) in THF (1 mL) was
added, and after stirring for 30 min, methyl iodide (0.009 mL,
0.146 mmol, 1.5 equiv) was added. The mixture was stirred for 30 min
at −20 °C and for 30 min at rt. H2O was added to the reaction mixture,
the aqueous phase was extracted with EtOAc, and the combined
organic layers were washed with brine (×3), dried over MgSO4, filtered,
and concentrated. The mixture was purified by silica gel column
chromatography (hexanes/EtOAc 65:35) afforded the title com-
pound as a yellow solid (0.009 g, 0.028 mmol, 29% yield). 1H NMR
(500 MHz, CDCl3) δ 7.38−7.33 (m, 2H), 7.19 (s, 1H), 7.11−7.04 (m,
3H), 6.78−6.73 (m, 1H), 2.34 (s, 3H) ppm. 13C NMR (126 MHz,
CDCl3) δ 155.73 (dt, J = 246.7, 3.2 Hz), 148.24 (ddd, J = 251.2, 14.2,
6.5 Hz), 147.45, 147.13 (ddd, J = 245.9, 13.2, 3.6 Hz), 134.95, 134.80,
130.14, 129.73, 128.32, 125.88, 119.63, 117.77−117.37 (m), 110.88
(ddd, J = 24.7, 6.9, 4.3 Hz), 109.67 (dd, J = 21.8, 16.1 Hz), 14.24 ppm.
IR (KBr) ν 3098, 3061, 2961, 2924, 2850, 1641, 1494, 1402, 1237,
1093 cm−1. HRMS (ES+) calculated for C16H11F3N2Cl [M + H]
+
323.0563, found 323.0568.
1-(4-Chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1H-imida-
zole (35). Following synthetic procedure D using (E)-N-(4-
chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (0.500 g, 1.85 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
60:40) afforded the title compound as an orange solid (0.190 g,
0.589 mmol, 32% yield). 1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H),
7.33−7.29 (m, 2H), 7.15 (qd, J = 9.1, 5.0 Hz, 1H), 7.07−7.02 (m, 2H),
6.85−6.79 (m, 1H), 2.22 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ
155.69 (dt, J = 247.2, 3.4 Hz), 148.15 (ddd, J = 252.2, 14.3, 6.4 Hz),
147.28 (ddd, J = 246.6, 12.8, 4.1 Hz), 140.74, 138.07, 135.11,
134.20, 129.79, 125.77, 117.83 (dd, J = 19.4, 9.7 Hz), 115.33 (d, J =
2.3 Hz), 111.14 (ddd, J = 24.4, 6.9, 4.2 Hz), 109.45 (dd, J = 22.0,
16.2 Hz), 13.48 ppm. IR (KBr) ν 3094, 2925, 1642, 1595, 1500, 1472,
1353, 1269, 1250, 1231, 1092, 1002, 973 cm−1. HRMS (ES+) calculated
for C16H11ClF3N2 [M + H]
+ 323.0563, found 323.0557.
2-Chloro-1-(4-chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-
1H-imidazole (36). Following synthetic procedure E using
1-(4-chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1H-imidazole
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(0.100 g, 0.310 mmol), purification by silica gel column chromatog-
raphy (hexanes/EtOAc 80:20) afforded the title compound as a white
solid (0.079 g, 0.221 mmol, 71% yield). 1H NMR (500 MHz, CDCl3)
δ 7.36−7.31 (m, 2H), 7.17−7.07 (m, 3H), 6.82−6.76 (m, 1H), 2.17 (s,
3H) ppm. 13C NMR (126 MHz, CDCl3) δ 155.82 (dt, J = 247.3,
2.9 Hz), 148.29 (ddd, J = 251.9, 14.1, 7.0 Hz), 147.12 (ddd, J = 246.7,
13.0, 3.9 Hz), 139.27, 135.37, 133.55 (d, J = 5.2 Hz), 129.85, 129.60,
128.57, 118.34 (dd, J = 19.3, 9.9 Hz), 117.60 (d, J = 2.3 Hz), 111.11
(ddd, J = 24.7, 6.9, 4.4 Hz), 108.90 (dd, J = 22.0, 16.2 Hz), 13.44 ppm.
IR (KBr) ν 3052, 2983, 2918, 2849, 1494, 1448, 1265, 1236, 1092,
1001 cm−1. HRMS (ES+) calculated for C16H10Cl2F3N2 [M + H]
+
357.0173, found 357.0170.
1-(4-Chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imida-
zole (37). Following synthetic procedure C using (E)-N-(4-chloro-3-
fluorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (0.431 g, 1.5 mmol),
purification by silica gel column chromatography (hexanes/EtOAc 100:0
to 50:50) afforded the title compound as an orange solid (0.385 g,
1.18 mmol, 79% yield). 1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H),
7.34 (t, J = 8.2 Hz, 1H), 7.27 (s, 1H), 7.09 (qd, J = 9.1, 5.0 Hz, 1H), 6.95
(dd, J = 9.1, 2.4 Hz, 1H), 6.87 (dd, J = 8.5, 1.0 Hz, 1H), 6.80−6.75 (m,
1H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.92, 156.92, 155.23 (dt,
J = 247.6, 2.8 Hz), 147.79 (ddd, J = 252.4, 14.5, 6.4 Hz), 147.14 (ddd, J =
246.3, 13.0, 3.6 Hz), 139.06, 135.89 (d, J = 8.8 Hz), 132.81, 131.35,
121.36, 121.22, 120.81 (d, J = 3.8 Hz), 119.00 (d, J = 1.6 Hz), 117.76
(dd, J = 19.6, 9.6 Hz), 113.15, 112.96, 111.14 (dt, J = 24.5, 5.4 Hz),
108.61 (dd, J = 21.6, 15.7 Hz) ppm. MS (ES+) calculated for
C15H8ClF4N2 [M + H]
+ 327.03, found 327.14.
2-Chloro-5-(5-(2,4,6-trifluorophenyl)-1H-imidazol-1-yl)pyridine
(38). Following synthetic procedure C using (E)-N-(6-chloropyridin-
3-yl)-1-(2,4,6-trifluorophenyl)methanimine (0.593 g, 2.2 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
100:0 to 60:40) afforded the title compound as an orange solid
(0.304 g, 0.982 mmol, 45% yield). 1H NMR (500 MHz, CDCl3)
δ 8.21 (s, 1H), 7.78 (s, 1H), 7.45 (ddd, J = 8.4, 2.5, 1.2 Hz, 1H),
7.35−7.33 (m, 1H), 7.28 (s, 1H), 6.66−6.63 (m, 2H) ppm. 13C NMR
(126 MHz, CDCl3) δ 163.30 (dt, J = 253.2, 15.2 Hz), 160.50 (ddd, J =
251.6, 14.8, 8.5 Hz), 151.19, 145.34, 138.80, 134.72, 132.82, 132.10,
124.96, 119.28, 102.94 (td, J = 19.9, 4.7 Hz), 101.23−100.79 (m) ppm.
MS (ES+) calculated for C14H8ClF3N3 [M + H]
+ 310.04, found 310.13.
1-(4-Chlorophenyl)-5-(4-fluorophenyl)-1H-imidazole (39). Fol-
lowing synthetic procedure C using (E)-N-(4-chlorophenyl)-1-(4-
fluorophenyl)methanimine (0.350 g, 1.5 mmol), purification by
silica gel column chromatography (hexanes/EtOAc 90:10 to 60:40)
afforded the title compound as a brown solid (0.260 g, 0.953 mmol,
64% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 (s, 1H), 7.39−7.36
(m, 2H), 7.22 (s, 1H), 7.12−7.08 (m, 4H), 7.00−6.96 (m, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 162.48 (d, J = 248.1 Hz), 138.79,
135.13, 134.36, 132.22, 130.18 (d, J = 8.2 Hz), 129.92, 129.20, 126.92,
125.39 (d, J = 3.2 Hz), 115.85 (d, J = 21.8 Hz) ppm. MS (ES+)
calculated for C15H11ClFN2 [M + H]
+ 273.06, found 273.25.
1-(4-Chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole
(40). Following synthetic procedure C using (E)-N-(4-chloro-2-
fluorophenyl)-1-(2,6-difluorophenyl)methanimine (0.539 g, 2 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
90:10 to 60:40) afforded the title compound as a yellow solid (0.351 g,
1.14 mmol, 57% yield). 1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H),
7.35 (s, 1H), 7.31−7.27 (m, 1H), 7.21−7.19 (m, 1H), 7.15−7.10
(m, J = 6.6 Hz, 2H), 6.88 (quintet, J = 6.8 Hz, 2H) ppm. 13C NMR
(126 MHz, CDCl3) δ 160.46 (dd, J = 250.9, 5.9 Hz), 156.39 (d, J =
256.0 Hz), 139.44 (d, J = 1.1 Hz), 135.42 (d, J = 9.2 Hz), 131.92,
130.94 (t, J = 10.3 Hz), 128.57, 125.17, 125.14, 123.30 (d, J =
12.7 Hz), 120.88, 117.86, 117.67, 111.71 (dd, J = 20.5, 5.2 Hz), 106.96
(t, J = 19.5 Hz) ppm. MS (ES+) calculated for C15H9ClF3N2 [M + H]
+
309.04, found 309.12.
1-(4-Chlorophenyl)-5-(2,5-difluorophenyl)-1H-imidazole (41).
Following synthetic procedure C using (E)-N-(4-chlorophenyl)-1-
(2,5-difluorophenyl)methanimine (0.378 g, 1.5 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 100:0 to
60:40) afforded the title compound as a yellow solid (0.392 g,
1.35 mmol, 90% yield). 1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H),
7.33 (d, J = 8.4 Hz, 2H), 7.29 (s, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.09−
7.07 (m, 2H), 6.86−6.83 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3)
δ 158.35 (dd, J = 248.6, 7.2 Hz), 155.45 (d, J = 244.1 Hz), 139.09,
135.05, 134.29, 131.29, 129.80, 126.02, 118.66 (dd, J = 17.7, 8.8 Hz),
117.30 (dd, J = 24.8, 3.1 Hz), 117.18 (dd, J = 24.8, 8.9 Hz), 116.56
(dd, J = 23.8, 8.3 Hz) ppm. MS (ES+) calculated for C15H10ClF2N2
[M + H]+ 291.05, found 291.04.
5-(2,6-Difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imida-
zole (42). Following synthetic procedure C using (E)-1-(2,6-
difluorophenyl)-N-(4-(trifluoromethoxy)phenyl)methanimine (1.03 g,
3.43 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 60:40) afforded the title compound as a white solid
(0.644 g, 1.89 mmol, 55% yield). 1H NMR (500 MHz, DMSO-d6) δ
8.20 (s, 1H), 7.54−7.47 (m, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.35 (d, J =
8.5 Hz, 2H), 7.32 (s, 1H), 7.15 (t, J = 8.2 Hz, 2H) ppm. 13C NMR
(126 MHz, DMSO-d6) δ 159.54 (dd, J = 248.4, 6.0 Hz), 147.54−
147.48 (m), 139.64, 135.08, 131.88, 131.76 (t, J = 5.2 Hz), 126.09,
122.12, 119.91 (q, J = 256.9 Hz), 118.93, 111.98 (dd, J = 20.4, 5.1 Hz),
106.56 (t, J = 19.7 Hz) ppm. IR (KBr) ν 3059, 2917, 2849, 1632, 1580,
1562, 1514, 1472, 1448, 1262, 1212, 1169 cm−1. HRMS (ES+)
calculated for C16H10F5N2O [M + H]
+ 341.0713, found 341.0714.
1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (43).
Following synthetic procedure C using (E)-N-(4-chlorophenyl)-1-
(2,6-difluorophenyl)methanimine (1.62 g, 6.45 mmol), purification by
silica gel column chromatography (hexanes/EtOAc 65:35) afforded
the title compound as a yellow solid (1.18 g, 4.04 mmol, 63% yield).
1H NMR (500 MHz, CDCl3) δ 8.86 (s, 1H), 7.60 (s, 1H), 7.49−7.44
(m, 1H), 7.44−7.40 (m, 2H), 7.21−7.17 (m, 2H), 6.99−6.93 (m, 2H)
ppm. 13C NMR (126 MHz, CDCl3) δ 160.46 (dd, J = 253.1, 5.2 Hz),
136.99, 136.90, 133.44 (t, J = 10.2 Hz), 132.54, 130.41, 126.30, 123.71,
122.62, 112.21 (dd, J = 20.4, 4.2 Hz), 103.71 (t, J = 19.4 Hz) ppm.
IR (KBr) ν 3104, 2919, 2851, 2612, 1987, 1680, 1590, 1536, 1491,
1469, 1414, 1348, 1148 cm−1. HRMS (ES+) calculated for
C15H10ClF2N2 [M + H]
+ 291.0501, found 291.0503.
1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1H-imida-
zole (44). Following synthetic procedure D using (E)-N-(4-chlorophen-
yl)-1-(2,6-difluorophenyl)methanimine (0.618 g, 2.46 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 65:35) afforded
the title compound as an orange solid (0.292 g, 0.958 mmol, 39% yield).
1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.36−7.28 (m, 1H),
7.32−7.25 (m, 2H), 7.08−7.01 (m, 2H), 6.93−6.83 (m, 2H), 2.21
(s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.61 (dd, J = 250.3,
6.3 Hz), 140.19, 137.61, 135.40, 133.91, 131.00 (t, J = 10.2 Hz),
129.63, 125.7, 116.13, 111.74 (dd, J = 20.1, 5.3 Hz), 107.53
(t, J = 20.0 Hz), 13.44 ppm. IR (KBr) ν 3105, 2921, 2851, 1692,
1630, 1590, 1569, 1498, 1479, 1461, 1274, 1235, 1091, 997 cm−1.
HRMS (ES+) calculated for C16H12ClF2N2 [M + H]
+ 305.0657, found
305.0661.
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1H-
imidazole (45). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1H-imidazole (0.150 g,
0.492 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 80:20) afforded the title compound as a yellow oil
(0.079 g, 0.232 mmol, 47% yield). 1H NMR (500 MHz, CDCl3) δ 7.31
(d, J = 8.6 Hz, 2H), 7.30−7.26 (m, 1H), 7.12−7.07 (m, 2H), 6.88−6.81
(m, 2H), 2.16 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.70
(dd, J = 250.6, 6.0 Hz), 138.71, 135.08, 133.82, 132.88, 131.46 (t, J =
10.2 Hz), 129.41, 128.60, 118.49, 111.65 (dd, J = 20.6, 5.1 Hz), 107.02
(t, J = 19.8 Hz), 13.37 ppm. IR (KBr) ν 3056, 2959, 2923, 2850, 1633,
1590, 1571, 1495, 1467, 1448, 1387, 1280, 1236, 1092, 998 cm−1.
HRMS (ES+) calculated for C16H11Cl2F2N2 [M + H]
+ 339.0267, found
339.0277.
1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-2,4-dimethyl-1H-imi-
dazole (46). Following synthetic procedure F using 1-(4-chlorophenyl)-
5-(2,6-difluorophenyl)-4-methyl-1H-imidazole (0.050 g, 0.164 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
65:35) afforded the title compound as a colorless liquid (0.025 g,
0.078 mmol, 48% yield). 1H NMR (500 MHz, CDCl3) δ 7.31−7.27 (m,
2H), 7.25−7.18 (m, 1H), 7.06−7.01 (m, 2H), 6.81 (t, J = 7.6 Hz, 2H),
2.29 (s, 3H), 2.14 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.79
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(dd, J = 249.7, 6.3 Hz), 145.79, 137.59, 135.43, 134.38, 130.69 (t, J =
10.2 Hz), 129.44, 128.40, 116.41, 111.49 (dd, J = 20.3, 5.3 Hz), 108.12
(t, J = 20.1 Hz), 14.09, 13.12 ppm. IR (KBr) ν 2958, 2923, 2851, 1633,
1594, 1572, 1495, 1464, 1403, 1274, 1235, 1092 cm−1. HRMS (ES+)
calculated for C17H14ClF2N2 [M + H]
+ 319.0814, found 319.0807.
1-(4-(Trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imi-
dazole (47). Following synthetic procedure C using (E)-N-(4-
(trifluoromethoxy)phenyl)-1-(2,3,6-trifluorophenyl)methanimine
(1.08 g, 3.37 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 65:35) afforded the title compound as a brown solid
(0.587 g, 1.64 mmol, 49% yield). 1H NMR (500 MHz, CDCl3) δ 7.83
(s, 1H), 7.36 (s, 1H), 7.26−7.17 (m, 4H), 7.14 (qd, J = 9.1, 4.9 Hz,
1H), 6.86−6.77 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 155.51
(dt, J = 247.8, 3.2 Hz), 149.06−148.90 (m), 148.12 (ddd, J = 261.9,
15.9, 9.2 Hz), 147.33 (ddd, J = 246.6, 12.7, 4.1 Hz), 139.36, 134.80,
132.76, 126.15, 122.02, 120.40 (q, J = 258.6 Hz), 119.39, 117.84 (dd,
J = 19.1, 9.6 Hz), 111.17 (ddd, J = 24.6, 6.7, 4.2 Hz), 109.03 (dd, J =
21.9, 15.9 Hz) ppm. IR (KBr) ν 3097, 2917, 2850, 1734, 1642, 1599,
1563, 1514, 1494, 1448, 1383, 1260, 1211, 1167, 1103, 1027, 1016,
994 cm−1. HRMS (ES+) calculated for C16H9F6N2O [M + H]
+
359.0619, found 359.0621.
1-(4-Chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imida-
zole (48). Following synthetic procedure C using (E)-N-(4-
chlorophenyl)-1-(2,6-difluoro-4-methylphenyl)methanimine (0.183 g,
0.689 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 60:40) afforded the title compound as a yellow solid
(0.127 g, 0.417 mmol, 61% yield). 1H NMR (500 MHz, CDCl3) δ
7.76 (s, 1H), 7.31 (d, J = 8.2 Hz, 2H), 7.26 (s, 1H), 7.08 (d, J =
8.3 Hz, 2H), 6.67 (d, J = 8.2 Hz, 2H), 2.32 (s, 3H) ppm. 13C NMR
(126 MHz, CDCl3) δ 160.10 (dd, J = 249.8, 7.0 Hz), 142.34 (t, J =
9.8 Hz), 138.65, 135.27, 134.11, 132.11, 129.68, 125.88, 120.32,
112.32 (dd, J = 19.8, 5.3 Hz), 104.03 (t, J = 19.8 Hz), 21.58 ppm.
IR (KBr) ν 3113, 3073, 3037, 2923, 2854, 1642, 1572, 1499, 1464,
1323, 1277, 1249, 1215, 1205, 1091 cm−1. HRMS (ES+) calculated for
C16H12ClF2N2 [M + H]
+ 305.0657, found 305.0658.
1-(4-Chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imida-
zole (49). Following synthetic procedure C using (E)-N-(4-
chlorophenyl)-1-(2,6-difluoro-3-methoxyphenyl)methanimine (0.745 g,
2.64 mmol), purification by silica gel column chromatography (hexanes/
EtOAc 60:40) afforded the title compound as a yellow solid (0.278 g,
0.867 mmol, 33% yield). 1H NMR (500 MHz, CDCl3) δ 7.79 (s, 1H),
7.35−7.29 (m, 3H), 7.10 (d, J = 8.1 Hz, 2H), 6.94−6.85 (m, 1H), 6.79
(t, J = 8.8 Hz, 1H), 3.83 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3)
δ 153.72 (dd, J = 243.6, 4.1 Hz), 149.74 (dd, J = 250.3, 5.9 Hz), 144.52
(dd, J = 11.1, 3.0 Hz), 138.92, 135.18, 134.20, 132.42, 129.73, 125.86,
120.12, 113.94 (dd, J = 9.4, 2.9 Hz), 110.40 (dd, J = 23.1, 4.3 Hz),
108.08 (dd, J = 21.4, 16.8 Hz), 56.86 ppm. IR (KBr) ν 3098, 2941,
2842, 1592, 1500, 1441, 1318, 1281, 1247, 1172, 1110, 1049 cm−1.
HRMS (ES+) calculated for C16H12ClF2N2O [M + H]
+ 321.0606, found
321.0606.
1-(4-Chlorophenyl)-5-phenyl-1H-imidazole (50). Following syn-
thetic procedure C using (E)-N-(4-chlorophenyl)-1-phenylmethanimine
(0.702 g, 3.25 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 60:40) afforded the title compound as a orange solid
(0.088 g, 0.345 mmol, 11% yield). 1H NMR (500 MHz, CDCl3) δ 7.67
(s, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.30−7.26 (m, 4H), 7.16−7.09 (m,
4H) ppm. 13C NMR (126 MHz, CDCl3) δ 138.80, 135.25, 134.08,
133.08, 129.77, 129.19, 129.15, 128.66, 128.28, 127.80, 126.84 ppm.
IR (KBr) ν 3115, 3062, 2957, 2921, 2851, 1604, 1495, 1468, 1269, 1117,
1093 cm−1. HRMS (ES+) calculated for C15H12ClN2 [M + H]
+
255.0689, found 255.0690.
1-(4-Chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazole (51). Fol-
lowing synthetic procedure C using (E)-N-(4-chlorophenyl)-1-(4-
methoxyphenyl)methanimine (0.100 g, 0.407 mmol), purification by
silica gel column chromatography (hexanes/EtOAc 65:35) afforded
the title compound as a orange solid (0.065 g, 0.228 mmol, 56% yield).
1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H), 7.38−7.30 (m, 2H), 7.18
(s, 1H), 7.14−7.07 (m, 2H), 7.08−6.99 (m, 2H), 6.85−6.75 (m, 2H),
3.78 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 159.35, 138.30,
135.38, 134.01, 132.95, 129.74, 128.50, 126.88, 121.62, 114.17,
55.35 ppm. IR (KBr) ν 3118, 3046, 2960, 2916, 2836, 1614, 1557,
1497, 1466, 1297, 1271, 1250, 1178, 1113, 1093, 1063, 1030 cm−1.
HRMS (ES+) calculated for C16H14ClN2O [M + H]
+ 285.0795, found
285.0798.
5-(2,6-Difluorophenyl)-1-phenyl-1H-imidazole (52). Following
synthetic procedure C using (E)-1-(2,6-difluorophenyl)-N-phenyl-
methanimine (0.600 g, 2.76 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 65:35) afforded the title compound
as an orange solid (0.193 g, 0.753 mmol, 27% yield). 1H NMR
(500 MHz, CDCl3) δ 7.84 (s, 1H), 7.41−7.34 (m, 3H), 7.34 (s, 1H),
7.34−7.25 (m, 1H), 7.21−7.15 (m, 2H), 6.91−6.83 (m, 2H) ppm. 13C
NMR (126 MHz, CDCl3) δ 160.55 (dd, J = 250.5, 6.2 Hz), 138.99,
136.71, 132.15, 130.67 (t, J = 10.2 Hz), 129.46, 128.25, 124.59, 120.06,
111.61 (dd, J = 20.4, 5.0 Hz), 107.65 (t, J = 19.7 Hz) ppm. IR (KBr)
ν 3103, 3070, 3045, 2916, 2848, 1631, 1597, 1563, 1498, 1470, 1447,
1278, 1255, 1236, 1216, 1116, 1077, 998 cm−1. HRMS (ES+)
calculated for C15H11F2N2 [M + H]
+ 257.0890, found 257.0881.
1-(2-Chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (53).
Following synthetic procedure C using (E)-N-(2-chlorophenyl)-1-
(2,6-difluorophenyl)methanimine (0.600 g, 2.38 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 65:35) afforded
the title compound as a yellow solid (0.478 g, 1.64 mmol, 69% yield).
1H NMR (500 MHz, CDCl3) δ 7.72 (s, 1H), 7.41−7.37 (m, 1H),
7.32−7.24 (m, 2H), 7.25−7.14 (m, 3H), 6.82−6.74 (m, 2H) ppm. 13C
NMR (126 MHz, CDCl3) δ 160.49 (dd, J = 250.9, 6.1 Hz), 139.5,
134.11, 131.55, 131.53, 130.68 (t, J = 10.2 Hz), 130.54, 130.13, 129.00,
127.44, 121.01, 111.52 (dd, J = 20.3, 5.0 Hz), 107.32 (t, J = 19.4 Hz)
ppm. IR (KBr) ν 3104, 3062, 1632, 1587, 1566, 1491, 1467, 1444,
1275, 1235, 1213, 1110, 1089, 1045, 999 cm−1. HRMS (ES+)
calculated for C15H10ClF2N2 [M + H]
+ 291.0501, found 291.0494.
4-Chloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1H-imida-
zole (54). Following synthetic procedure E using 1-(4-chlorophenyl)-
5-(2,4,6-trifluorophenyl)-1H-imidazole (0.400 g, 1.3 mmol), purifica-
tion by silica gel column chromatography (hexanes/EtOAc 100:0 to
70:30) afforded the title compound as a white solid (0.305 g,
0.889 mmol, 69% yield). 1H NMR (500 MHz, CDCl3) δ 7.68 (s, 1H),
7.36−7.33 (m, 2H), 7.09−7.07 (m, 2H), 6.71−6.65 (m, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 163.93 (dt, J = 253.4, 15.3 Hz),
161.04 (ddd, J = 253.0, 15.1, 8.4 Hz), 136.90, 135.09, 134.44, 132.62,
129.98, 126.00, 115.23, 101.87 (td, J = 20.3, 4.8 Hz), 101.21−100.77
(m) ppm. IR (KBr) ν 3050, 2987, 2919, 2848, 1646, 1595, 1498, 1444,
1265, 1125, 1037, 908, 735 cm−1. HRMS (ES+) calculated for
C15H8Cl2F3N2 [M + H]
+ 343.0017, found 343.0008.
4-Chloro-1-(4-chlorophenyl)-2-methyl-5-(2,4,6-trifluorophenyl)-
1H-imidazole (55). Following synthetic procedure F using 4-chloro-1-
(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (0.100 g,
0.290 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 90:10 to 70:30) afforded the title compound as a
white solid (9 mg, 9% yield). 1H NMR (500 MHz, CDCl3) δ 7.81 (s,
1H), 7.37 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 6.66 (t, J =
9.0 Hz, 1H), 2.12 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ
163.87 (dt, J = 253.2, 15.3 Hz, 1C), 161.27 (ddd, J = 252.3, 15.1,
8.5 Hz), 145.85, 135.65, 134.21, 130.25, 129.96, 128.37, 115.30,
102.36 (td, J = 20.6, 4.2 Hz), 101.05−100.60 (m), 14.02 ppm.
IR (KBr) ν 2962, 2927, 2852, 1644, 1585, 1495, 1442, 1400, 1122,
1038, 999 cm−1. HRMS (ES+) calculated for C16H10Cl2F3N2 [M + H]
+
357.0173, found 357.0171.
2-Chloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1H-imida-
zole (56). Following synthetic procedure E using 1-(4-chlorophenyl)-
5-(2,4,6-trifluorophenyl)-1H-imidazole (0.400 g, 1.3 mmol), purifica-
tion by silica gel column chromatography (hexanes/EtOAc 100:0 to
70:30) afforded the title compound as a white solid (0.058 g,
0.169 mmol, 13% yield). 1H NMR (500 MHz, CDCl3) δ 7.37−7.34
(m, 2H), 7.16 (s, 1H), 7.11 (d, J = 8.6 Hz, 2H), 6.64−6.58 (m, 2H)
ppm. 13C NMR (126 MHz, CDCl3) δ 163.54 (dt, J = 253.0, 15.2 Hz),
161.05 (ddd, J = 251.8, 15.1, 8.4 Hz), 135.66, 134.53, 133.38, 130.58,
129.69, 128.62, 121.59, 103.44 (td, J = 20.1, 4.6 Hz), 100.99−100.54
(m) ppm. IR (KBr) ν 3459, 1645, 1599, 1568, 1495, 1447, 1124,
1034 cm−1. HRMS (ES+) calculated for C15H8Cl2F3N2 [M + H]
+
343.0017, found 343.0022.
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2,4-Dichloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1H-imi-
dazole (57). Following synthetic procedure E using 1-(4-chlorophenyl)-
5-(2,4,6-trifluorophenyl)-1H-imidazole (0.400 g, 1.3 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 100:0 to 70:30)
afforded the title compound as a white solid (0.016 g, 0.042 mmol, 3%
yield). 1H NMR (500 MHz, CDCl3) δ 7.39−7.36 (m, 2H), 7.12 (d, J =
8.6 Hz, 2H), 6.69−6.63 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ
164.23 (dt, J = 254.2, 15.3 Hz), 161.26 (ddd, J = 253.1, 15.1, 8.3 Hz),
136.22, 132.94, 132.88, 130.83, 129.91, 128.57, 117.68, 101.61 (td, J =
20.2, 4.9 Hz), 101.23−100.78 (m) ppm. IR (KBr) ν 3100, 3067,
2962, 2928, 2857, 1645, 1599, 1495, 1446, 1121, 1038, 998 cm−1.
HRMS (ES+) calculated for C15H7Cl3F3N2 [M + H]
+ 376.9627, found
376.9627.
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methoxyphen-
yl)-1H-imidazole (58). To a solution of 2,4-dichloro-1-(4-chlorophenyl)-
5-(2,4,6-trifluorophenyl)-1H-imidazole (0.032 g, 0.085 mmol) in THF
(0.53 mL) at 0 °C was added a 30% sodium methoxide solution in
MeOH (0.031 mL). The reaction mixture was stirred for 16 h at rt,
then quenched with an aqueous ammonium chloride solution and
extracted with EtOAc (3×). The combined organic layers were dried
(Na2SO4), filtered, and concentrated. The crude products were purified
by preparative reverse-phase HPLC to obtain the title compound as a
white solid (0.011 g, 0.028 mmol, 33% yield). 1H NMR (500 MHz,
CDCl3) δ 7.38−7.35 (m, 2H), 7.12 (d, J = 8.6 Hz, 2H), 6.41 (q, J =
7.3 Hz, 2H), 3.78 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 162.97
(t, J = 14.0 Hz), 161.59 (dd, J = 249.7, 9.1 Hz), 135.90, 133.24, 132.20,
130.42, 129.75, 118.83, 101.00 (td, J = 26.4, 3.1 Hz), 98.46−98.24 (m),
97.03 (t, J = 20.6 Hz), 56.07 ppm. IR (KBr) ν 3390, 2965, 2924, 2848,
1644, 1574, 1495, 1445, 1384, 1352, 1150 cm−1. HRMS (ES+)
calculated for C16H10Cl3F2N2O [M + H]
+ 388.9827, found 388.9830.
4-Chloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imi-
dazole (59). Following synthetic procedure E using 1-(4-methox-
yphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (0.086 g, 0.283 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
80:20) afforded the title compound as a yellow solid (0.043 g,
0.127 mmol, 45% yield). 1H NMR (500 MHz, CDCl3) δ 77.64 (s, 1H),
7.06 (d, J = 8.6 Hz, 2H), 6.88−6.82 (m, 2H), 6.71−6.61 (m, 2H),
3.79 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.80 (dt,
J = 252.7, 15.1 Hz), 161.21 (ddd, J = 252.7, 15.3, 8.6 Hz), 159.90,
137.20, 131.91, 128.82, 126.27, 115.50, 114.71, 102.27 (td, J = 20.4,
4.7 Hz), 101.15−100.40 (m), 55.62 ppm. IR (KBr) ν 3149, 3047,
2983, 2941, 2916, 2838, 1644, 1595, 1564, 1517, 1468, 1439, 1249,
1179, 1128, 1028 cm−1. HRMS (ES+) calculated for C16H11ClF3N2O
[M + H]+ 339.0512, found 339.0481.
2-Chloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imi-
dazole (60). Following synthetic procedure E using 1-(4-methox-
yphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (0.086 g, 0.283 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
80:20) afforded the title compound as a yellow solid (0.015 g,
0.044 mmol, 16% yield). 1H NMR (500 MHz, CDCl3) δ 7.14 (s, 1H),
7.11−7.06 (m, 2H), 6.89−6.84 (m, 2H), 6.64−6.56 (m, 2H), 3.81 (s,
3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.34 (dt, J = 252.7,
15.4 Hz), 161.13 (ddd, J = 251.5, 15.0, 8.5 Hz), 160.07, 134.94,
130.16, 128.51, 127.52, 121.78, 114.42, 103.86 (td, J = 20.3, 4.7 Hz),
101.08−100.00 (m), 55.59 ppm. IR (KBr) ν 3053, 2962, 2917, 2847,
1645, 1596, 1570, 1514, 1485, 1448, 1253, 1171, 1124, 1035 cm−1.
HRMS (ES+) calculated for C16H11ClF3N2O [M + H]
+ 339.0512, found
339.0499.
2,4-Dichloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-
imidazole (61). Following synthetic procedure E using 1-(4-
methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1H-imidazole (0.086 g,
0.283 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 80:20) afforded the title compound as a yellow solid
(0.010 g, 0.027 mmol, 9% yield). 1H NMR (500 MHz; CDCl3) δ
7.11−7.06 (m, 2H), 6.89−6.84 (m, 2H), 6.67−6.60 (m, 2H), 3.81 (s,
3H) ppm. 13C NMR (126 MHz, CDCl3) δ 164.01 (dt, J = 253.2,
15.2 Hz), 161.30 (ddd, J = 252.8, 14.8, 8.5 Hz), 160.40, 133.20,
131.10, 130.15, 128.99, 128.46, 127.07, 117.87, 114.60, 101.95 (td, J =
20.2, 4.6 Hz), 101.36−100.34 (m), 55.63 ppm. IR (KBr) ν 2960, 2918,
2849, 1643, 1513, 1445, 1255, 1121, 1036 cm−1. HRMS (ES+)
calculated for C16H10Cl2F3N2O [M + H]
+ 373.0122, found 373.0112.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1H-
imidazole (62). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1H-imidazole (0.326 g,
1.07 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a
beige solid (0.187 g, 0.551 mmol, 52% yield). 1H NMR (500 MHz,
CDCl3) δ 7.73 (s, 1H), 7.36−7.33 (m, 2H), 7.22 (q, J = 7.5 Hz, 1H),
7.14−7.11 (m, 2H), 6.81 (td, J = 8.5, 0.9 Hz, 1H), 2.22 (s, 3H) ppm.
13C NMR (126 MHz, CDCl3) δ 158.49 (ddd, J = 249.9, 12.8, 5.7 Hz),
136.49, 134.57, 134.56, 133.20 (dd, J = 9.5, 7.1 Hz), 131.96, 129.69,
125.74, 121.03 (dd, J = 17.6, 3.8 Hz), 116.38, 110.95 (dd, J = 21.2, 3.9
Hz), 104.53 (t, J = 20.1 Hz), 14.10 (d, J = 3.2 Hz) ppm. IR (KBr) ν
3121, 3096, 2924, 2852, 1497, 1482, 1265, 1093, 958 cm−1. HRMS
(ES+) calculated for C16H11Cl2F2N2 [M + H]
+ 339.0267, found
339.0269.
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1H-
imidazole (63). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1H-imidazole (0.326 g,
1.07 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a
brown solid (0.030 g, 0.088 mmol, 8% yield). 1H NMR (500 MHz,
CDCl3) δ 7.35−7.32 (m, 2H), 7.16 (s, 1H), 7.14−7.08 (m, 3H), 6.71
(td, J = 8.5, 1.1 Hz, 1H), 2.15 (s, 3H) ppm. 13C NMR (126 MHz,
CDCl3) δ 158.66 (ddd, J = 248.9, 13.9, 5.4 Hz), 135.30, 134.12,
133.71, 132.66 (t, J = 8.2 Hz), 130.33, 129.48, 128.68, 123.01, 120.95
(dd, J = 18.0, 4.0 Hz), 110.88 (dd, J = 21.7, 3.8 Hz), 106.33 (t, J =
20.1 Hz), 14.27 (d, J = 3.1 Hz) ppm. IR (KBr) ν 3445, 2919,
2848, 1496, 1478, 1443, 1093, 1042 cm−1. HRMS (ES+) calculated for
C16H11Cl2F2N2 [M + H]
+ 339.0267, found 339.0257.
4-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-
imidazole (64). Following synthetic procedure E using 5-(3-chloro-
2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imidazole (0.280 g,
0.434 mmol, 0.861 mmol), purification by silica gel column chromato-
graphy (hexanes/EtOAc 100:0 to 80:20) afforded the title compound
as a yellow solid (0.156 g, 0.434 mmol, 50% yield). 1H NMR
(500 MHz, CDCl3) δ 7.69 (s, 1H), 7.41 (td, J = 8.6, 5.6 Hz, 1H),
7.34−7.31 (m, 2H), 7.09 7.06 (m, 2H), 6.88−6.84 (m, 1H) ppm.
13C NMR (126 MHz, CDCl3) δ 158.79 (dd, J = 252.6, 4.4 Hz), 155.89
(dd, J = 253.6, 6.2 Hz), 137.09, 135.05, 134.27, 132.65, 132.28 (d, J =
9.6 Hz), 129.97, 125.85, 117.26 (dd, J = 18.4, 4.1 Hz), 115.25, 112.37
(dd, J = 23.3, 4.2 Hz), 106.79 (t, J = 20.1 Hz) ppm. IR (KBr) ν 3121,
3104, 3075, 2932, 2848, 1558, 1497, 1472, 1453, 1267, 1092 cm−1.
HRMS (ES+) calculated for C15H8Cl3F2N2 [M + H]
+ 358.9721, found
358.9724.
4-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-2-
methyl-1H-imidazole (65). Following synthetic procedure F using
4-chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imi-
dazole (0.078 g, 0.216 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title
compound as a brown solid (0.039 g, 0.104 mmol, 48% yield). 1H
NMR (500 MHz, CDCl3) δ 7.38−7.33 (m, 3H), 7.07 (d, J = 8.6 Hz,
2H), 6.83−6.79 (m, 1H), 2.30 (s, 3H) ppm. 13C NMR (126 MHz,
CDCl3) δ 159.02 (dd, J = 251.5, 4.4 Hz), 156.10 (dd, J = 252.9,
6.3 Hz), 146.08, 135.50, 134.14, 132.05 (d, J = 9.6 Hz), 130.54,
129.91, 128.29, 117.08 (dd, J = 18.5, 4.1 Hz), 115.24, 112.19 (dd, J =
23.5, 4.4 Hz), 107.42 (t, J = 20.5 Hz), 14.06 ppm. IR (KBr) ν 3100,
3071, 2928, 2848, 1558, 1495, 1465, 1399, 1495, 1465, 1399, 1338,
1287, 1242, 1219, 1092, 1011, 997 cm−1. HRMS (ES+) calculated for
C16H10Cl3F2N2 [M + H]
+ 372.9878, found 372.9864.
2-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-
imidazole (66). Following synthetic procedure E using 5-(3-chloro-
2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imidazole (0.280 g,
0.861 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a
yellow solid (0.050 g, 0.139 mmol, 16% yield). 1H NMR (500 MHz,
CDCl3) δ 7.37−7.32 (m, 3H), 7.20 (s, 1H), 7.14−7.11 (m, 2H), 6.80
(td, J = 8.6, 1.4 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.83
(dd, J = 251.3, 4.1 Hz), 155.97 (dd, J = 252.5, 6.2 Hz), 135.64, 134.85,
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133.35, 131.78, 131.70, 130.88, 129.69, 128.57, 121.65, 117.22 (dd, J =
18.6, 4.1 Hz), 112.19 (dd, J = 23.6, 4.3 Hz), 108.44 (t, J = 20.3 Hz)
ppm. IR (KBr) ν 3100, 3071, 2928, 2857, 1683, 1652, 1635,
1558, 1538, 1495 cm−1. HRMS (ES+) calculated for C15H8Cl3F2N2
[M + H]+ 358.9721, found 358.9717.
5-(3-Bromo-2,6-difluorophenyl)-4-chloro-1-(4-chlorophenyl)-1H-
imidazole (67). Following synthetic procedure E using 5-(3-bromo-
2,6-difluorophenyl)-1-(4-chlorophenyl)-1H-imidazole (0.452 g,
1.223 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a
brown solid (0.224 g, 0.554 mmol, 45% yield). 1H NMR (500 MHz,
CDCl3) δ 7.68 (s, 1H), 7.55 (ddd, J = 8.9, 7.7, 5.8 Hz, 1H), 7.33−7.31
(m, 2H), 7.08−7.06 (m, 2H), 6.83−6.79 (m, 1H) ppm. 13C NMR
(126 MHz, CDCl3) δ 159.51 (dd, J = 252.8, 4.5 Hz), 156.83 (dd, J =
252.0, 6.2 Hz), 137.04, 135.14, 135.07, 135.06 (d, J = 1.3 Hz), 135.06,
135.00, 134.23, 132.59, 129.93, 125.81, 115.25, 112.89 (dd, J = 22.8,
4.2 Hz, 1C), 106.70 (t, J = 20.7 Hz), 104.44 (dd, J = 21.8, 4.3 Hz)
ppm. IR (KBr) ν 3092, 2915, 2848, 1558, 1497, 1471, 1327, 1267,
1216, 1090, 1015, 999, 959 cm−1. HRMS (ES+) calculated for
C15H8BrCl2F2N2 [M + H]
+ 402.9216, found 402.9217.
4-Chloro-1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imida-
zole (68). Following synthetic procedure E using 1-(4-chlorophenyl)-
5-(2,3,6-trifluorophenyl)-1H-imidazole (0.406 g, 1.316 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
100:0 to 80:20) afforded the title compound as a beige solid (0.244 g,
0.711 mmol, 55% yield). 1H NMR (500 MHz, CDCl3) δ 7.69 (s, 1H),
7.33−7.31 (m, 2H), 7.18 (qd, J = 9.1, 5.0 Hz, 1H), 7.09−7.07 (m,
2H), 6.85−6.80 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 155.66
(dt, J = 248.9, 2.9 Hz), 148.20 (ddd, J = 253.9, 14.4, 6.4 Hz), 147.08
(ddd, J = 246.5, 12.7, 3.7 Hz), 137.12, 135.02, 134.27, 132.63, 129.92,
125.83, 118.88 (dd, J = 19.6, 9.5 Hz), 115.11 (d, J = 1.9 Hz), 111.25
(ddd, J = 24.1, 6.5, 4.4 Hz), 107.09 (dd, J = 21.5, 15.8 Hz) ppm.
IR (KBr) ν 3054, 2987, 2924, 2852, 1499, 1265, 739, 704 cm−1.
HRMS (ES+) calculated for C15H8Cl2F3N2 [M + H]
+ 343.0017, found
343.0005.
2-Chloro-1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imida-
zole (69). Following synthetic procedure E using 1-(4-chlorophenyl)-
5-(2,3,6-trifluorophenyl)-1H-imidazole (0.406 g, 1.316 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
100:0 to 80:20) afforded the title compound as a brown solid (0.220 g,
0.641 mmol, 5% yield). 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J =
8.6 Hz, 2H), 7.22 (s, 1H), 7.16−7.08 (m, 3H), 6.81−6.76 (m, 1H)
ppm. 13C NMR (126 MHz, CDCl3) δ 155.76 (dt, J = 247.8, 3.0 Hz),
148.33 (ddd, J = 252.7, 14.5, 6.2 Hz), 147.14 (ddd, J = 246.7, 13.0, 3.7
Hz), 135.73, 134.93, 133.32, 130.74, 130.06, 129.72, 128.59, 121.62,
118.53−118.29 (m), 111.11 (ddd, J = 24.5, 6.5, 4.4 Hz), 108.71 (dd,
J = 21.7, 15.9 Hz) ppm. IR (KBr) ν 3092, 3058, 2924, 2857, 1496,
1461, 1433, 1318, 1235, 1094 cm−1. HRMS (ES+) calculated for
C15H8Cl2F3N2 [M + H]
+ 343.0017, found 343.0007.
4-Chloro-1-(4-chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-
1H-imidazole (70). Following synthetic procedure E using 1-(4-
chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (0.370 g,
1.13 mmol), purification by silica gel column chromatography (hexanes/
EtOAc 100:0 to 60:40) afforded the title compound as a yellow solid
(0.126 g, 0.349 mmol, 31% yield). 1H NMR (500 MHz, CDCl3) δ 7.72
(s, 1H), 7.40 (t, J = 8.1 Hz, 1H), 7.22 (qd, J = 9.1, 5.0 Hz, 1H), 6.99
(dd, J = 8.8, 2.3 Hz, 1H), 6.91 (dd, J = 8.5, 1.0 Hz, 1H), 6.89−6.84 (m,
1H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.05 (d, J = 252.6 Hz),
155.63 (dt, J = 248.8, 2.8 Hz), 148.20 (ddd, J = 254.0, 14.4,
6.4 Hz), 147.17 (ddd, J = 246.9, 12.7, 3.7 Hz), 137.11, 135.29 (d, J =
8.7 Hz), 133.06, 131.69, 122.28, 122.14, 121.01 (d, J = 3.8 Hz), 119.14
(dd, J = 19.9, 9.7 Hz), 115.09 (d, J = 1.5 Hz), 113.32 (d, J = 24.0 Hz),
111.42 (ddd, J = 24.1, 6.6, 4.3 Hz), 106.82 (dd, J = 21.5, 15.9 Hz) ppm.
IR (KBr) ν 3126, 3096, 3058, 2915, 2848, 1497, 1266, 1225, 1197, 1004,
888, 863, 814, 738 cm−1. HRMS (ES+) calculated for C15H7Cl2F4N2
[M + H]+ 360.9922, found 360.9917.
4-Chloro-1-(4-chloro-3-fluorophenyl)-2-methyl-5-(2,3,6-trifluoro-
phenyl)-1H-imidazole (71). Following synthetic procedure F using
4-chloro-1-(4-chloro-3-fluorophenyl)-5-(2,3,6- trifluorophenyl)-1H-
imidazole (0.100 g, 0.277 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 100:0 to 90:10) afforded the title
compound as a white solid (0.014 g, 0.037 mmol, 13% yield). 1H
NMR (500 MHz, CDCl3) δ 7.43 (t, J = 8.1 Hz, 1H), 7.17 (qd, J = 9.1,
5.0 Hz, 1H), 6.99 (dd, J = 8.8, 2.2 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H),
6.84−6.80 (m, 1H), 2.33 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3)
δ 158.00 (d, J = 253.0 Hz), 155.94 (dt, J = 248.2, 3.0 Hz), 148.48
(ddd, J = 253.4, 14.4, 6.3 Hz), 147.17 (ddd, J = 244.4, 12.9, 3.8 Hz),
146.11, 135.15 (d, J = 8.6 Hz), 131.59, 130.83, 123.69 (d, J = 3.8 Hz),
122.96 (d, J = 17.4 Hz), 118.97 (dd, J = 19.6, 9.8 Hz), 115.86 (d, J =
23.1 Hz), 115.23 (d, J = 2.1 Hz), 111.22 (ddd, J = 24.3, 6.7, 4.3 Hz),
107.44 (dd, J = 21.9, 16.1 Hz), 14.05 ppm. IR (KBr) ν 1493, 1435,
1394, 1249, 1234, 1222, 1077, 1058, 997 cm−1. HRMS (ES+)
calculated for C16H9Cl2F4N2 [M + H]
+ 375.0079, found 375.0070.
2-Chloro-1-(4-chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-
1H-imidazole (72). Following synthetic procedure E using 1-(4-
chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole (0.370 g,
1.13 mmol), purification by silica gel column chromatography (hexanes/
EtOAc 100:0 to 60:40) afforded the title compound as a yellow solid
(0.074 g, 0.205 mmol, 18% yield). 1H NMR (500 MHz, CDCl3) δ 7.42
(t, J = 8.1 Hz, 1H), 7.21 (s, 1H), 7.14 (qd, J = 9.0, 5.0 Hz, 1H), 7.05
(dd, J = 8.8, 2.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.81 (tdd, J = 8.7, 3.3,
1.9 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 157.84 (d, J = 252.4
Hz), 155.60 (dt, J = 248.0, 2.9 Hz), 148.19 (ddd, J = 253.1, 14.6, 6.0
Hz), 147.11 (ddd, J = 247.0, 12.8, 3.6 Hz), 134.77, 134.25 (d, J = 8.6
Hz), 131.23, 131.08, 123.87 (d, J = 3.8 Hz), 122.93, 122.79, 121.47 (d,
J = 1.3 Hz), 118.53 (dd, J = 19.2, 9.9 Hz), 116.11 (d, J = 23.5 Hz),
111.23 (ddd, J = 24.4, 6.5, 4.4 Hz), 108.37 (dd, J = 21.6, 15.9 Hz) ppm.
IR (KBr) ν 3094, 3058, 2932, 2860, 1587, 1494, 1459, 1426, 1313, 1238,
1074, 1009 cm−1. HRMS (ES+) calculated for C15H7Cl2F4N2 [M + H]
+
360.9922, found 360.9917.
2-Chloro-5-(4-chloro-5-(2,4,6-trifluorophenyl)-1H-imidazol-1-yl)-
pyridine (73). Following synthetic procedure E using 2-chloro-5-(5-
(2,4,6-trifluorophenyl)-1H-imidazol-1-yl)pyridine (0.304 g, 0.98 mmol),
purification by silica gel column chromatography (hexanes/EtOAc 100:0
to 70:30) afforded the title compound as a brown solid (0.172 g,
0.500 mmol, 51% yield). 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J =
2.7 Hz, 1H), 7.71 (s, 1H), 7.47 (dd, J = 8.4, 2.6 Hz, 1H), 7.37 (d, J =
8.4 Hz, 1H), 6.71 (t, J = 8.0 Hz, 2H) ppm. 13C NMR (126 MHz,
CDCl3) δ 164.22 (dt, J = 254.5, 15.2 Hz), 160.97 (ddd, J = 253.1, 15.1,
8.4 Hz), 151.97, 145.53, 136.91, 134.87, 133.36, 131.72, 125.18, 115.41,
101.48−101.04 (m) ppm. IR (KBr) ν 3100, 3058, 1646, 1599, 1575,
1558 cm−1. HRMS (ES+) calculated for C14H7Cl2F3N3 [M + H]
+
343.9969, found 343.9976.
2-Chloro-5-(4-chloro-2-methyl-5-(2,4,6-trifluorophenyl)-1H-imi-
dazol-1-yl)pyridine (74). Following synthetic procedure F using
2-chloro-5-(4-chloro-5-(2,4,6-trifluorophenyl)-1H-imidazol-1-yl)-
pyridine (0.120 g, 0.349 mmol), purification by reverse-phase HPLC
afforded the title compound as a white solid (0.003 g, 0.008 mmol, 2%
yield). 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 2.6 Hz, 1H), 7.48
(dd, J = 8.4, 2.6 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 6.68 (t, J = 8.0 Hz,
2H), 2.38 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 164.28 (dt,
J = 254.7, 15.4 Hz), 161.13 (ddd, J = 252.8, 15.0, 8.4 Hz), 152.78,
152.31, 147.82, 146.34, 145.63, 137.11, 134.97, 131.20, 130.32, 125.31,
115.88, 101.21 (td, J = 26.1, 3.8 Hz), 13.68 ppm. IR (KBr) ν
3067, 2962, 2924, 1733, 1683, 1646, 1558, 1539, 1506 cm−1. HRMS
(ES+) calculated for C15H9Cl2F3N3 [M + H]
+ 358.0126, found
358.0123.
2-Chloro-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-imidazole
(75). Following synthetic procedure E using 1-(4-chlorophenyl)-5-(4-
fluorophenyl)-1H-imidazole (0.124 g, 0.455 mmol), purification by
silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20)
afforded the title compound as a yellow solid (0.009 g, 0.029 mmol,
7% yield). 1H NMR (500 MHz, CDCl3) δ 7.58 (s, 1H), 7.37−7.31 (m,
4H), 7.20−7.19 (m, 2H), 7.06 (d, J = 8.0 Hz, 2H) ppm. 13C NMR
(126 MHz, CDCl3) δ 162.62 (d, J = 249.6 Hz), 135.75, 135.01,
134.79, 134.58, 131.70 (d, J = 8.3 Hz), 130.05, 129.94, 129.81, 128.65,
128.49, 127.38, 126.69, 126.66, 116.02, 115.84 ppm. IR (KBr) ν
3067, 2924, 2852, 1562, 1496 cm−1. HRMS (ES+) calculated for
C15H10Cl2FN2 [M + H]
+ 307.0205, found 307.0210.
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4-Chloro-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-imidazole
(76). Following synthetic procedure E using 1-(4-chlorophenyl)-5-(4-
fluorophenyl)-1H-imidazole (0.124 g, 0.455 mmol), purification by
silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20)
afforded the title compound as a white solid (0.060 g, 0.195 mmol,
43% yield). 1H NMR (500 MHz, CDCl3) δ 7.57 (s, 1H), 7.36−7.33
(m, 2H), 7.18−7.15 (m, 2H), 7.06−6.99 (m, 4H) ppm. 13C NMR
(126 MHz, CDCl3) δ 162.58 (d, J = 249.6 Hz), 135.74, 134.73 (d, J =
3.7 Hz), 131.66 (d, J = 8.2 Hz), 129.99, 129.33, 126.66, 126.23, 123.39
(d, J = 3.4 Hz), 115.96, 115.78 ppm. IR (KBr) ν 3117, 3062, 2962,
2916, 2848, 1683, 1652, 1599, 1575, 1558, 1497 cm−1. HRMS (ES+)
calculated for C15H10Cl2FN2 [M + H]
+ 307.0205, found 307.0206.
2-Chloro-1-(4-chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1H-
imidazole (77). Following synthetic procedure E using 1-(4-chloro-2-
fluorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (0.351 g, 1.14 mmol),
purification by silica gel column chromatography (hexanes/EtOAc 100:0
to 80:20) afforded the title compound as a yellow solid (0.025 g,
0.073 mmol, 6% yield). 1H NMR (500 MHz, CDCl3) δ 7.31−7.26 (m,
1H), 7.22 (s, 1H), 7.19 (d, J = 9.3 Hz, 1H), 7.15 (d, J = 3.1 Hz, 2H), 6.85
(t, J = 7.6 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.60 (dd, J =
251.4, 5.9 Hz), 157.37 (d, J = 257.9 Hz), 136.78 (d, J = 9.2 Hz), 134.86,
131.52 (t, J = 10.3 Hz), 130.78, 130.32, 125.13, 125.10, 122.95, 121.74 (d,
J = 13.0 Hz), 117.73 (d, J = 23.1 Hz), 111.69 (dd, J = 20.5, 5.0 Hz),
106.50 (t, J = 19.5 Hz) ppm. IR (KBr) ν 3104, 3071, 2936, 2860, 1683,
1652, 1634, 1587, 1558, 1538, 1505 cm−1. HRMS (ES+) calculated for
C15H8Cl2F3N2 [M + H]
+ 343.0017, found 343.0013.
4-Chloro-1-(4-chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1H-
imidazole (78). Following synthetic procedure E using 1-(4-chloro-2-
fluorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (0.351 g, 1.14 mmol),
purification by silica gel column chromatography (hexanes/EtOAc 100:0
to 80:20) afforded the title compound as a yellow solid (0.126 g,
0.367 mmol, 32% yield). 1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H),
7.38−7.33 (m, 1H), 7.19−7.17 (m, 1H), 7.13 (q, J = 6.4 Hz, 2H), 6.90 (t,
J = 7.8 Hz, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.74 (dd, J =
252.5, 5.9 Hz), 156.36 (d, J = 256.9 Hz), 137.49, 136.16 (d, J = 9.2 Hz),
132.18, 132.13 (t, J = 10.1 Hz), 128.61, 125.34 (d, J = 3.7 Hz), 122.69 (d,
J = 12.6 Hz), 117.87 (d, J = 22.8 Hz), 116.88, 111.80 (dd, J = 20.6,
4.5 Hz), 105.04 (t, J = 19.6 Hz) ppm. IR (KBr) ν 3105, 2932, 1683, 1652,
1634, 1590, 1568, 1506 cm−1. HRMS (ES+) calculated for C15H8Cl2F3N2
[M + H]+ 343.0017, found 343.0018.
2-Chloro-1-(4-chlorophenyl)-5-(2,5-difluorophenyl)-1H-imidazole
(79). Following synthetic procedure E using 1-(4-chlorophenyl)-5-
(2,5-difluorophenyl)-1H-imidazole (0.300 g, 1.03 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 100:0 to 50:50)
afforded the title compound as a yellow solid (0.010 g, 0.031 mmol,
3% yield). 1H NMR (500 MHz, CDCl3) δ 7.41−7.38 (m, 2H), 7.22 (s,
1H), 7.15−7.12 (m, 2H), 6.98−6.94 (m, 2H), 6.81−6.77 (m, 1H)
ppm. 13C NMR (126 MHz, CDCl3) δ 158.39 (dd, J = 245.6, 4.0 Hz),
155.71 (dd, J = 247.1, 3.7 Hz), 135.57, 134.62, 133.73, 129.79, 129.68
(d, J = 2.8 Hz), 128.87, 128.49, 118.43 (dd, J = 16.0, 10.3 Hz),
117.45−116.90 (m) ppm. IR (KBr) ν 3071, 2932, 2857, 1495 cm−1.
HRMS (ES+) calculated for C15H9Cl2F2N2 [M + H]
+ 325.0111, found
325.0110.
4-Chloro-1-(4-chlorophenyl)-5-(2,5-difluorophenyl)-1H-imidazole
(80). Following synthetic procedure E using 1-(4-chlorophenyl)-5-
(2,5-difluorophenyl)-1H-imidazole (0.300 g, 1.03 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 100:0 to 50:50)
afforded the title compound as a yellow solid (0.030 g, 0.092 mmol,
9% yield). 1H NMR (500 MHz, CDCl3) δ 7.64 (s, 1H), 7.35−7.33 (m,
2H), 7.10−7.03 (m, 4H), 6.96 (td, J = 8.8, 4.5 Hz, 1H) ppm. 13C
NMR (126 MHz, CDCl3) δ 158.48 (dd, J = 244.1, 2.0 Hz), 155.77
(dd, J = 246.1, 1.7 Hz), 144.02, 136.41, 134.84, 134.79, 131.12, 129.97,
129.80, 129.45, 127.34, 125.83, 123.07, 121.05, 118.61 (dd, J = 24.9,
2.7 Hz), 117.94 (dd, J = 24.0, 8.5 Hz), 117.36 (dd, J = 24.5, 8.9 Hz),
116.91 (dd, J = 18.1, 9.0 Hz) ppm. IR (KBr) ν 3126, 3100, 3067, 2924,
2857, 1733, 1683, 1652, 1558, 1539, 1497 cm−1. HRMS (ES+)
calculated for C15H9Cl2F2N2 [M + H]
+ 325.0111, found 325.0095.
4-Chloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-
1H-imidazole (81). Following synthetic procedure E using 5-(2,6-
difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole (0.400 g,
1.17 mmol), purification by silica gel column chromatography (hexanes/
EtOAc 85:15) afforded the title compound as a white solid (0.192 g,
0.512 mmol, 44% yield). 1H NMR (500 MHz, CDCl3) δ 7.70 (s, 1H),
7.43−7.33 (m, 1H), 7.24−7.16 (m, 4H), 6.91 (t, J = 7.8 Hz, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 160.71 (dd, J = 252.1, 6.0 Hz), 149.23−
149.16 (m), 136.84, 134.52, 132.53, 132.20 (t, J = 10.2 Hz), 126.25,
122.01, 120.39 (q, J = 238.7 Hz), 116.18, 111.88 (dd, J = 20.5,
5.1 Hz), 105.32 (t, J = 19.7 Hz) ppm. IR (KBr) ν 3121, 3088, 1632,
1588, 1565, 1513, 1473, 1330, 1259, 1212, 1169, 1099 cm−1. HRMS
(ES+) calculated for C16H9ClF5N2O [M + H]
+ 375.0324, found 375.0334.
2-Chloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-
1H-imidazole (82). Following synthetic procedure E using 5-(2,6-
difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole (0.400 g,
1.17 mmol), purification by silica gel column chromatography (hexanes/
EtOAc 85:15) afforded the title compound as a white solid (0.033 g,
0.088 mmol, 8% yield). 1H NMR (500 MHz, CDCl3) δ 7.34−7.25 (m,
1H), 7.27−7.20 (m, 4H), 7.20 (s, 1H), 6.88−6.82 (m, 2H) ppm. 13C
NMR (126 MHz, CDCl3) δ 160.59 (dd, J = 251.3, 5.8 Hz), 149.51−
149.44 (m), 134.36, 133.35, 131.57 (t, J = 10.2 Hz), 130.53, 128.96,
122.52, 121.41, 120.39 (q, J = 259.6 Hz), 111.67 (dd, J = 21.2,
4.6 Hz), 106.84 (t, J = 19.5 Hz) ppm. IR (KBr) ν 3077, 2920, 2852,
1632, 1586, 1511, 1469, 1436, 1388, 1261, 1211, 1172, 1001 cm−1.
HRMS (ES+) calculated for C16H8ClF5N2NaO [M + Na]
+ 397.0143,
found 397.0149.
2,4-Dichloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)-
phenyl)-1H-imidazole (83). Following synthetic procedure E using
5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-imidazole
(0.400 g, 1.17 mmol), purification by silica gel column chromatog-
raphy (hexanes/EtOAc 85:15) afforded the title compound as a white
solid (0.028 g, 0.068 mmol, 6% yield). 1H NMR (500 MHz, CDCl3)
δ 7.40−7.30 (m, 1H), 7.27−7.19 (m, 4H), 6.91−6.84 (m, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 160.74 (dd, J = 252.3, 5.6 Hz),
149.85−149.77 (m), 132.76, 132.65, 132.61 (t, J = 10.3 Hz), 130.50,
128.96, 121.54, 120.34 (q, J = 258.7 Hz), 118.60, 111.81 (dd, J = 21.0,
4.3 Hz), 104.93 (t, J = 19.4 Hz) ppm. IR (KBr) ν 3079, 2921, 2851,
1633, 1590, 1570, 1511, 1468, 1439, 1388, 1263, 1213, 1174 cm−1.
HRMS (ES+) calculated for C16H8Cl2F5N2O [M + H]
+ 408.9934,
found 408.9940.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole
(84). Following synthetic procedure E using 1-(4-chlorophenyl)-5-
(2,6-difluorophenyl)-1H-imidazole (0.400 g, 1.38 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 85:15) afforded
the title compound as a white solid (0.265 g, 0.815 mmol, 59% yield).
1H NMR (500 MHz, CDCl3) δ 7.69 (s, 1H), 7.41−7.35 (m, 1H), 7.33
(d, J = 8.0 Hz, 2H), 7.12−7.05 (m, 2H), 6.91 (t, J = 7.9 Hz, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 160.67 (dd, J = 252.0, 5.9 Hz),
136.75, 134.89, 134.65, 132.40, 132.12 (t, J = 10.1 Hz), 129.91, 125.93,
116.10, 111.88 (dd, J = 21.1, 4.3 Hz), 105.36 (t, J = 19.5 Hz) ppm.
IR (KBr) ν 3128, 2917, 2849, 1631, 1587, 1564, 1497, 1470, 1453,
1383, 1265, 1236, 1091, 998 cm−1. HRMS (ES+) calculated for
C15H9Cl2F2N2 [M + H]
+ 325.0111, found 325.0122.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-2-methyl-1H-
imidazole (85). Following synthetic procedure F using 4-chloro-1-(4-
chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (0.050 g, 0.154 mmol),
purification by silica gel column chromatography (hexanes/EtOAc 80:20)
afforded the title compound as a white solid (0.020 g, 0.059 mmol, 38%
yield). 1H NMR (500 MHz, CDCl3) δ 7.37−7.31 (m, 2H), 7.31−7.27
(m, 1H), 7.08 (d, J = 8.6 Hz, 2H), 6.89−6.82 (m, 2H), 2.31 (s, 3H) ppm.
13C NMR (126 MHz, CDCl3) δ 160.83 (dd, J = 250.5, 6.9 Hz), 145.60,
135.23, 134.48, 131.79 (t, J = 10.1 Hz), 130.20, 129.75, 128.37, 116.02,
111.63 (dd, J = 20.4, 4.8 Hz), 105.96 (t, J = 17.7 Hz), 14.13 ppm. IR (KBr)
ν 3064, 2960, 2921, 2850, 1634, 1576, 1494, 1467, 1402, 1278, 1238, 1093,
999 cm−1. HRMS (ES+) calculated for C16H11Cl2F2N2 [M + H]
+ 339.0267,
found 339.0265.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-2-ethyl-1H-
imidazole (86). Following synthetic procedure F using 4-chloro-1-(4-
chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (0.040 g, 0.123 mmol),
purification by silica gel column chromatography (hexanes/EtOAc 85:15)
afforded the title compound as a white solid (0.015 g, 0.042 mmol, 35%
yield). 1H NMR (500 MHz, CDCl3) δ 7.36−7.30 (m, 2H), 7.30−7.27
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(m, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.87−6.81 (m, 2H), 2.58 (q, J = 7.5 Hz,
2H), 1.26 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3)
δ 160.87 (dd, J = 251.5, 5.8 Hz), 150.43, 135.27, 134.34, 131.77 (t, J =
10.3 Hz), 130.33, 129.71, 128.59, 115.90, 111.61 (dd, J = 20.7, 5.4 Hz),
105.96 (t, J = 20.3 Hz), 21.16, 12.21 ppm. IR (KBr) ν 3070, 2973, 2923,
2852, 1633, 1586, 1494, 1468, 1411, 1276, 1238, 1092, 1001 cm−1. HRMS
(ES+) calculated for C17H13Cl2F2N2 [M + H]
+ 353.0424, found 353.0429.
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole
(87). Following synthetic procedure E using 1-(4-chlorophenyl)-5-
(2,6-difluorophenyl)-1H-imidazole (0.400 g, 1.38 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 85:15) afforded
the title compound as a white solid (0.056 g, 0.172 mmol, 12% yield).
1H NMR (500 MHz, CDCl3) δ 7.36−7.31 (m, 2H), 7.31−7.23 (m,
1H), 7.18 (s, 1H), 7.12 (d, J = 8.2 Hz, 2H), 6.84 (t, J = 7.9 Hz, 2H)
ppm. 13C NMR (126 MHz, CDCl3) δ 160.33 (dd, J = 251.1, 5.8 Hz),
135.10, 134.03, 133.32, 131.24 (t, J = 10.3 Hz), 130.21, 129.27, 128.36,
122.21, 111.39 (dd, J = 20.4, 4.8 Hz), 106.64 (t, J = 19.5 Hz) ppm.
IR (KBr) ν 3098, 3063, 2919, 2847, 1632, 1585, 1564, 1495, 1468,
1434, 1384, 1315, 1276, 1235, 1092, 1001 cm−1. HRMS (ES+)
calculated for C15H8Cl2F2N2Na [M + Na]
+ 346.9930, found 346.9933.
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imi-
dazole (88). Following synthetic procedure E using 1-(4-chlorophen-
yl)-5-(2,6-difluorophenyl)-1H-imidazole (0.400 g, 1.38 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
85:15) afforded the title compound as a white solid (0.026 g,
0.072 mmol, 5% yield). 1H NMR (500 MHz, CDCl3) δ 7.39−7.30 (m,
3H), 7.13 (d, J = 8.1 Hz, 2H), 6.88 (t, J = 8.0 Hz, 2H) ppm. 13C NMR
(126 MHz, CDCl3) δ 160.75 (dd, J = 252.3, 5.6 Hz), 135.94, 133.03,
132.59, 132.54 (t, J = 10.2 Hz), 130.43, 129.75, 128.57, 118.55, 111.81
(dd, J = 21.2, 4.2 Hz), 105.00 (t, J = 19.7 Hz) ppm. IR (KBr) ν 2961,
2918, 2850, 1632, 1589, 1568, 1495, 1468, 1434, 1384, 1262, 1236,
1092, 1003 cm−1. HRMS (ES+) calculated for C15H8Cl3F2N2
[M + H]+ 358.9721, found 358.9725.
4-Chloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophen-
yl)-1H-imidazole (89). Following synthetic procedure E using 1-(4-
(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole
(0.500 g, 1.40 mmol), purification by silica gel column chromatog-
raphy (hexanes/EtOAc 85:15) afforded the title compound as a yellow
oil (0.198 g, 0.504 mmol, 36% yield). 1H NMR (500 MHz, CDCl3) δ
7.72 (s, 1H), 7.25−7.17 (m, 5H), 6.88−6.82 (m, 1H) ppm. 13C NMR
(126 MHz, CDCl3) δ 155.78 (dt, J = 248.9, 3.1 Hz), 149.38−149.32
(m), 148.35 (ddd, J = 253.2, 14.1, 6.8 Hz), 147.23 (ddd, J = 247.2,
12.8, 3.7 Hz), 137.27, 134.21, 132.94, 126.29, 122.13, 120.36 (q, J =
258.7 Hz), 119.05 (dd, J = 19.2, 9.6 Hz), 115.30, 111.35 (ddd, J = 24.2,
6.8, 4.2 Hz), 107.15 (dd, J = 21.7, 15.8 Hz) ppm. IR (KBr) ν 3095,
2918, 2850, 1568, 1513, 1493, 1467, 1383, 1162, 1110, 999 cm−1.
HRMS (ES+) calculated for C16H7ClF6N2NaO [M + Na]
+ 415.0049,
found 415.0059.
2-Chloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophen-
yl)-1H-imidazole (90). Following synthetic procedure E using 1-(4-
(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imidazole
(0.500 g, 1.40 mmol), purification by silica gel column chromatog-
raphy (hexanes/EtOAc 85:15) afforded the title compound as a yellow
solid (0.047 g, 0.120 mmol, 9% yield). 1H NMR (500 MHz, CDCl3) δ
7.29−7.24 (m, 5H), 7.16 (qd, J = 9.1, 5.0 Hz, 1H), 6.86−6.78 (m, 1H)
ppm. 13C NMR (126 MHz, CDCl3) δ 155.69 (dt, J = 248.0, 3.1 Hz),
149.67−149.59 (m), 148.28 (ddd, J = 252.4, 14.7, 5.9 Hz), 147.13
(ddd, J = 246.5, 12.4, 3.6 Hz), 134.96, 133.11, 130.95, 128.93, 121.59,
121.52, 120.37 (q, J = 258.7 Hz), 118.40 (dd, J = 19.2, 9.7 Hz), 111.10
(ddd, J = 24.3, 6.7, 4.1 Hz), 108.67 (dd, J = 21.8, 15.9 Hz) ppm. IR
(KBr) ν 3081, 2920, 1511, 1493, 1460, 1433, 1387, 1260, 1211, 1172,
1113, 1018, 998 cm−1. HRMS (ES+) calculated for C16H8ClF6N2O
[M + H]+ 393.0229, found 393.0232.
2,4-Dichloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluoro-
phenyl)-1H-imidazole (91). Following synthetic procedure E using
1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1H-imida-
zole (0.500 g, 1.40 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 85:15) afforded the title compound
as a yellow solid (0.010 g, 0.023 mmol, 2% yield). 1H NMR
(600 MHz, DMSO-d6) δ 7.72−7.63 (m, 1H), 7.57 (d, J = 8.8 Hz, 2H),
7.53−7.48 (m, 2H), 7.27−7.21 (m, 1H) ppm. 13C NMR (151 MHz,
DMSO-d6) δ 155.16 (dt, J = 248.0, 3.1 Hz), 148.96 (q, J = 2.0 Hz),
147.29 (ddd, J = 252.1, 14.5, 6.2 Hz), 146.31 (ddd, J = 244.4, 12.4,
4.1 Hz), 133.01, 132.51, 129.62, 129.15, 122.11, 120.66 (dd, J = 19.3,
9.7 Hz), 119.87 (q, J = 258.7 Hz), 119.55, 112.27 (ddd, J = 24.2, 7.6,
4.4 Hz), 105.61 (dd, J = 22.5, 16.2 Hz) ppm. IR (KBr) ν 2919, 2850,
1642, 1383, 1247, 1179 cm−1. HRMS (ES+) calculated for
C16H7Cl2F6N2O [M + H]
+ 426.9840, found 426.9850.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-
imidazole (92). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (0.100 g,
0.328 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 85:15) afforded the title compound as a yellow
solid (0.070 g, 0.206 mmol, 63% yield). 1H NMR (500 MHz, CDCl3) δ
7.67 (s, 1H), 7.35−7.29 (m, 2H), 7.11−7.05 (m, 2H), 6.71 (d, J =
8.4 Hz, 2H), 2.35 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.37
(dd, J = 251.2, 6.9 Hz), 143.68 (t, J = 9.9 Hz), 136.56, 134.77, 134.75,
132.25, 129.86, 125.96, 116.31, 112.46 (dd, J = 20.3, 4.9 Hz), 102.16 (t,
J = 19.8 Hz), 21.74 ppm. IR (KBr) ν 3064, 2922, 1644, 1568, 1496,
1412, 1321, 1265, 1205, 1086, 1037 cm−1. HRMS (ES+) calculated for
C16H11Cl2F2N2 [M + H]
+ 339.0267, found 339.0259.
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-
imidazole (93). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (0.100 g,
0.328 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 85:15) afforded the title compound as a yellow
solid (0.009 g, 0.026 mmol, 8% yield). 1H NMR (500 MHz, CDCl3) δ
7.38−7.31 (m, 2H), 7.18−7.10 (m, 3H), 6.65 (d, J = 8.5 Hz, 2H), 2.31
(s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.30 (dd, J = 250.0,
6.7 Hz), 143.00 (t, J = 9.9 Hz), 135.27, 134.04, 133.66, 130.31, 129.52,
128.68, 122.73, 112.24 (dd, J = 21.0, 4.4 Hz), 103.73 (t, J = 19.4 Hz),
21.68 ppm. IR (KBr) ν 2918, 2850, 1644, 1494, 1440, 1383, 1315,
1205, 1094, 1039 cm−1. HRMS (ES+) calculated for C16H11Cl2F2N2
[M + H]+ 339.0267, found 339.0263.
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-
1H-imidazole (94). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1H-imidazole (0.100 g,
0.328 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 85:15) afforded the title compound as a yellow
solid (0.024 g, 0.064 mmol, 20% yield). 1H NMR (500 MHz, CDCl3) δ
7.35 (d, J = 8.3 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 6.68 (d, J = 8.5 Hz,
2H), 2.33 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 160.45 (dd,
J = 251.3, 6.7 Hz), 144.17 (t, J = 9.9 Hz), 135.85, 133.15, 132.32,
130.31, 129.72, 128.61, 118.80, 112.40 (dd, J = 20.2, 4.1 Hz), 101.84
(t, J = 20.0 Hz), 21.79 ppm. IR (KBr) ν 3065, 2924, 2853, 1645,
1573, 1493, 1436, 1385, 1324, 1263, 1237, 1206, 1093, 1040 cm−1.
HRMS (ES+) calculated for C16H10Cl3F2N2 [M + H]
+ 372.9878, found
372.9869.
4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-
1H-imidazole (95). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole (0.132 g,
0.412 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 80:20) afforded the title compound as white foam
(0.065 g, 0.183 mmol, 45% yield). 1H NMR (500 MHz, CDCl3) δ 7.67
(s, 1H), 7.32 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 8.3 Hz, 2H), 6.96 (td, J =
9.2, 5.0 Hz, 1H), 6.85−6.77 (m, 1H), 3.83 (s, 3H) ppm. 13C NMR
(126 MHz, CDCl3) δ 153.82 (dd, J = 244.9, 3.7 Hz), 149.93 (dd,
J = 251.9, 5.9 Hz), 144.49 (dd, J = 10.6, 2.7 Hz), 136.77, 134.84, 134.59,
132.37, 129.88, 125.92, 116.10, 114.96 (dd, J = 9.5, 2.1 Hz), 110.52 (dd,
J = 22.6, 4.3 Hz), 106.13 (dd, J = 21.1, 16.7 Hz), 56.81 ppm. IR (KBr) ν
3097, 2925, 2843, 1591, 1563, 1495, 1463, 1440, 1328, 1257, 1203,
1094, 1070 cm−1. HRMS (ES+) calculated for C16H11Cl2F2N2O
[M + H]+ 355.0217, found 355.0203.
2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-
1H-imidazole (96). Following synthetic procedure E using 1-(4-
chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole (0.132 g,
0.412 mmol), purification by silica gel column chromatography
(hexanes/EtOAc 80:20) afforded the title compound as a yellow solid
(0.015 g, 0.042 mmol, 10% yield). 1H NMR (500 MHz, CDCl3) δ
7.38−7.31 (m, 2H), 7.18 (s, 1H), 7.16−7.11 (m, 2H), 6.88 (td, J = 9.1,
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5.0 Hz, 1H), 6.80−6.72 (m, 1H), 3.82 (s, 3H) ppm. 13C NMR
(126 MHz, CDCl3) δ 153.85 (dd, J = 243.6, 4.2 Hz), 149.92 (dd, J =
250.9, 5.9 Hz), 144.38 (dd, J = 11.0, 3.4 Hz), 135.36, 134.38, 133.55,
130.48, 129.57, 128.66, 122.51, 114.40 (dd, J = 9.5, 3.2 Hz), 110.34 (dd,
J = 23.3, 4.4 Hz), 107.70 (dd, J = 21.2, 16.9 Hz), 56.84 ppm. IR (KBr) ν
3096, 2923, 2849, 1590, 1493, 1459, 1438, 1383, 1318, 1244, 1175,
1123, 1093, 1058 cm−1. HRMS (ES+) calculated for C16H11Cl2F2N2O
[M + H]+ 355.0217, found 355.0219.
2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphen-
yl)-1H-imidazole (97). Following synthetic procedure E using
1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1H-imidazole
(0.132 g, 0.412 mmol), purification by silica gel column chromatog-
raphy (hexanes/EtOAc 80:20) afforded the title compound as a yellow
solid (0.009 g, 0.023 mmol, 6% yield). 1H NMR (500 MHz, CDCl3) δ
7.37−7.34 (m, 2H), 7.15−7.12 (m, 2H), 6.94 (td, J = 9.2, 5.0 Hz, 1H),
6.81−6.77 (m, 1H), 3.83 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3)
δ 153.94 (dd, J = 244.9, 4.0 Hz), 150.12 (dd, J = 252.5, 5.6 Hz), 144.45
(dd, J = 10.6, 3.4 Hz), 135.95, 133.06, 132.65, 130.49, 129.78, 128.61,
118.59, 115.43 (dd, J = 9.8, 3.0 Hz), 110.51 (dd, J = 22.8, 4.3 Hz),
105.84 (dd, J = 21.4, 16.8 Hz), 56.88 ppm. IR (KBr) ν 2921, 2850,
1639, 1494, 1440, 1384, 1331, 1251, 1090 cm−1. HRMS (ES+)
calculated for C16H10Cl3F2N2O [M + H]
+ 388.9827, found 388.9832.
4-Chloro-1-(4-chlorophenyl)-5-phenyl-1H-imidazole (98). Follow-
ing synthetic procedure E using 1-(4-chlorophenyl)-5-phenyl-1H-
imidazole (0.070 g, 0.275 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 80:20) afforded the title compound
as a yellow solid (0.061 g, 0.211 mmol, 77% yield). X-ray quality
crystals were obtained by slow evaporation from a CH2Cl2/hexanes
solution (see Supporting Information): mp (CH2Cl2/hexanes)
126−128 °C. 1H NMR (500 MHz, CDCl3) δ 7.58 (s, 1H), 7.36−
7.29 (m, 5H), 7.22−7.16 (m, 2H), 7.09−7.02 (m, 2H) ppm. 13C NMR
(126 MHz, CDCl3) δ 135.72, 134.91, 134.49, 129.89, 129.75, 129.24,
128.62, 128.44, 127.28, 127.09, 126.61 ppm. IR (KBr) ν 3121, 3096,
3034, 2917, 2849, 1607, 1558, 1497, 1483, 1467, 1413, 1329, 1259,
1199, 1090 cm−1. HRMS (ES+) calculated for C15H11Cl2N2 [M + H]
+
289.0299, found 289.0300.
2-Chloro-1-(4-chlorophenyl)-5-phenyl-1H-imidazole (99). Follow-
ing synthetic procedure E using 1-(4-chlorophenyl)-5-phenyl-1H-
imidazole (0.070 g, 0.275 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 80:20) afforded the title compound
as a yellow solid (0.007 g, 0.025 mmol, 9% yield). 1H NMR (500 MHz,
CDCl3) δ 7.45−7.38 (m, 2H), 7.27−7.22 (m, 3H), 7.20−7.12 (m, 3H),
7.10−7.03 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 135.32,
134.09, 133.77, 129.85, 129.37, 128.95, 128.76, 128.12, 127.94, 127.21,
125.13 ppm. IR (KBr) ν 2956, 2918, 2850, 1487, 1457, 1432, 1383,
1307, 1256, 1146, 1146, 1093 cm−1. HRMS (ES+) calculated for
C15H11Cl2N2 [M + H]
+ 289.0299, found 289.0324.
2,4-Dichloro-1-(4-chlorophenyl)-5-phenyl-1H-imidazole (100).
Following synthetic procedure E using 1-(4-chlorophenyl)-5-phenyl-
1H-imidazole (0.070 g, 0.275 mmol), purification by silica gel column
chromatography (hexanes/EtOAc 80:20) afforded the title compound
as a yellow solid (0.008 g, 0.024 mmol, 9% yield). 1H NMR (500 MHz,
CDCl3) δ 7.40−7.36 (m, 2H), 7.30−7.27 (m, 3H), 7.16−7.12 (m, 2H),
7.12−7.08 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 135.64,
133.57, 131.34, 129.89, 129.59, 129.21, 128.71, 128.65, 127.20,
127.05 ppm. IR (KBr) ν 2956, 2917, 2849, 1493, 1452, 1381, 1230,
1091 cm−1. HRMS (ES+) calculated for C15H10Cl3N2 [M + H]
+
322.9910, found 322.9906.
4-Chloro-1-(4-chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazole
(101). Following synthetic procedure E using 1-(4-chlorophenyl)-5-(4-
methoxyphenyl)-1H-imidazole (0.220 g, 0.773 mmol), purification by
silica gel column chromatography (hexanes/EtOAc 80:20) afforded
the title compound as a yellow solid (0.159 g, 0.498 mmol, 65% yield).
1H NMR (500 MHz, CDCl3) δ 7.55 (s, 1H), 7.36−7.31 (m, 2H), 7.11
(d, J = 8.1 Hz, 2H), 7.06 (d, J = 7.9 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H),
3.79 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 159.66, 135.29,
135.02, 134.43, 131.15, 129.87, 128.71, 127.05, 126.64, 119.49, 114.17,
55.36 ppm. IR (KBr) ν 3116, 3004, 2960, 2836, 1713, 1614, 1556,
1497, 1467, 1290, 1253, 1179, 1087 cm−1. HRMS (ES+) calculated for
C16H12Cl2N2NaO [M + Na]
+ 341.0224, found 341.0229.
4-Chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole
(102). Following synthetic procedure E using 1-(2-chlorophenyl)-5-
(2,6-difluorophenyl)-1H-imidazole (0.260 g, 0.894 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 75:25) afforded
the title compound as a white solid (0.187 g, 0.575 mmol, 64% yield).
1H NMR (500 MHz, CDCl3) δ 7.63 (s, 1H), 7.42 (d, J = 7.9 Hz, 1H),
7.36−7.29 (m, 2H), 7.29−7.26 (m, 2H), 6.85 (t, J = 8.6 Hz, 2H) ppm.
13C NMR (126 MHz, CDCl3) δ 160.77 (dd, J = 252.5, 5.9 Hz),
137.58, 133.55, 131.88 (t, J = 10.2 Hz), 131.70, 131.67, 130.73, 130.61,
129.10, 127.60, 117.02, 111.64 (dd, J = 21.8, 3.6 Hz), 105.35
(t, J = 19.5 Hz) ppm. IR (KBr) ν 3129, 3052, 2988, 2922, 2846, 1633,
1589, 1568, 1492, 1471, 1455, 1266, 1238, 1003 cm−1. HRMS (ES+)
calculated for C15H9Cl2F2N2 [M + H]
+ 325.0111, found 325.0111.
2-Chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole
(103). Following synthetic procedure E using 1-(2-chlorophenyl)-5-
(2,6-difluorophenyl)-1H-imidazole (0.260 g, 0.894 mmol), purification
by silica gel column chromatography (hexanes/EtOAc 75:25) afforded
the title compound as a white solid (0.026 g, 0.080 mmol, 9% yield).
1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 8.0 Hz, 1H), 7.36−7.27
(m, 3H), 7.25−7.16 (m, 2H), 6.79 (t, J = 7.7 Hz, 2H) ppm. 13C NMR
(126 MHz, CDCl3) δ 160.72 (dd, J = 251.5, 5.8 Hz), 134.75, 133.21,
132.81, 131.34 (t, J = 10.2 Hz), 131.06, 130.51, 130.44, 130.32, 127.44,
122.84, 111.53 (dd, J = 20.6, 5.1 Hz), 106.87 (t, J = 19.5 Hz) ppm.
IR (KBr) ν 2916, 2852, 1633, 1587, 1487, 1468, 1435, 1383, 1313,
1277, 1235, 1000 cm−1. HRMS (ES+) calculated for C15H9Cl2F2N2
[M + H]+ 325.0111, found 325.0119.
2,4-Dichloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1H-imi-
dazole (104). Following synthetic procedure E using 4-chloro-1-(2-
chlorophenyl)-5-(2,6-difluorophenyl)-1H-imidazole (0.060 g, 0.184 mmol),
purification by silica gel column chromatography (hexanes/EtOAc
80:20) afforded the title compound as a white solid (0.047 g,
0.131 mmol, 71% yield). 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J =
7.9 Hz, 1H), 7.40−7.27 (m, 4H), 6.88 (t, J = 8.5 Hz, 1H), 6.82 (t, J =
8.6 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 161.07 (dd, J =
254.4, 5.9 Hz), 133.11, 133.08, 132.37 (t, J = 11.2 Hz), 131.53, 130.56,
130.39, 130.24, 130.22, 127.62, 118.89, 111.95 (dd, J = 21.7, 3.5 Hz),
111.41 (dd, J = 21.8, 3.7 Hz), 104.92 (t, J = 19.8 Hz) ppm. IR (KBr)
ν 3073, 2918, 2853, 1633, 1588, 1487, 1466, 1439, 1384, 1278, 1237,
1002 cm−1. HRMS (ES+) calculated for C15H8Cl3F2N2 [M + H]
+
358.9721, found 358.9717.
Acetyl-Tubulin Assay. QBI-293 cells (ATCC, Manassas, VA,
USA) were maintained in Dulbecco’s Modified Eagle’s Medium
(Mediatech Inc., Manassas, VA, USA) containing 10% fetal bovine
serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, USA), 2 mM
L-glutamine (Mediatech), 50 units/mL penicillin, and 50 μg/mL
streptomycin (1% penicillin/streptomycin; Thermo Fisher Scientific,
Waltham, MA, USA). Cells were maintained at 37 °C in a humidified
atmosphere (5% CO2) for all experiments. For compound testing, cells
were dissociated with trypsin/EDTA (Thermo Fisher Scientific) and
plated at 6 × 105 cells/well in 6-well plates. The medium was aspirated
after overnight incubation and fresh medium containing vehicle or
test compound was added. After incubating for 4 h, cells were washed
once with 1× phosphate-buffered saline (PBS), pH 7.4 and then
lysed in 200 μL RIPA buffer containing protease inhibitor cocktail,
1 mM PMSF, and 1 μM TSA. Lysed cells were scraped into 1.5 mL
Beckman ultracentrifuge tubes (Beckman, Brea, CA, USA) and
centrifuged at 100000g for 30 min at 4 °C. Following centrifugation,
the supernatant from each sample was collected and analyzed for
protein content by BCA assay. The samples subsequently underwent
analysis for acetyl-tubulin and α-tubulin levels by ELISA, as previously
described.39
RBL-1 Cell PG and LT Assay. Inhibition of PG and LT synthesis
by test compounds was determined through the utilization of an
established RBL-1 cell assay.40 Briefly, RBL-1 cells (ATCC) were
maintained in RPMI 1640 medium (Mediatech Inc., Manassas, VA)
containing 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Lawrenceville, GA), 1 mM L-glutamine (Mediatech), 50 U/mL
penicillin, and 0.05 mg/mL streptomycin (Thermo Fisher Scientific).
For analysis of PG and LT production, RBL-1 cells were plated at a
density of 9 × 105 cells/well in 24-well plates. After 2 h incubation at
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37 °C, cells were added with indicated concentrations of test
compounds. Following 2 h incubation with test compounds, cells
were incubated with 12 μM calcium ionophore, A23187, for 15 min
to induce arachidonic acid production. Cell culture supernatants
(200 μL/well) were then collected and treated with 600 μL of MeOH
containing 0.01% BHT (butylated hydroxytoluene) to extract
eicosanoids. After centrifugation, the supernatant was dried with a
vacuum centrifugation and redissolved in 200 μL of 50% acetonitrile.
Enzyme products were quantified with an Acquity UPLC-TQ MS
system (Waters Corporation, Milford, MA). Injections (10 μL) were
separated on an Acquity BEH C18, 1.7 μm, 2.1 mm × 50 mm column
at 37 °C using a gradient from 5 to 95% acetonitrile with 10 mM
ammonium formate over 2 min at 0.6 mL/min. Combined
PGD2+PGE2, as well as LTB4, were detected in negative ion mode
using compound specific collision induced mass transitions (PGD2 and
PGE2, 351 > 315; LTB4, 335 > 195). To separate the isomeric
prostaglandins PGD2 and PGE2, a higher resolution gradient from
5 to 60% acetonitrile over 3 min at 0.6 mL/min was used. The cysteinyl
leukotriene LTC4 was separated using a gradient from 5 to 95%
acetonitrile with 0.1% formic acid over 2 min at 0.6 mL/min. LTC4
was detected using electrospray ionization in positive mode while
monitoring for a compound specific mass transition (626 > 189).
Chromatograms are integrated and peak areas used to quantitate
unknowns against a curve of standards (Cayman Chemical, Ann Arbor,
MI) from 1 to 50 ng/mL in 50% acetonitrile.
Brain and Plasma Compound Determinations. All animal
protocols were approved by the University of Pennsylvania Institu-
tional Animal Care and Use Committee (IACUC). Test compounds
were administered to groups of three 2−5 month old CD-1 or B6SJL
mice, with both female and male mice used but not mixed within
experimental groups. For standard single time-point brain and plasma
determinations, mice were injected i.p. with a single dose of 5 mg/kg
compound dissolved in DMSO, or a dose of 2 mg/kg if two or three
compounds were dosed concurrently (cassette dosing). Compounds
were quantified in plasma and brain homogenates as previously
described.39
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